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burden 
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pocket 
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1. China 8123.2 697 5.1 60.3 5 34.6 6.2 
2. India 1709.6 253 4.5 31.3 2.4 65.6 7.9 
3. Indonesia 3570.3 265 2.5 42.7 2.7 53.5 5.5 
4. Pakistan 1443.6 132 2.7 32.1 6.1 55.4 5.8 
5. Egypt 3477.9 581 5.4 39.9 1.5 58.3 5.5 
6. USA 57638.2 9237 16.6 49.6 38.8 11.4 1.9 
7. Bangladesh 1358.8 92 2.9 22.7 0 65.6 7.0 
8. Russian 
Federation 8748.4 1877 7.1 51.8 2.8 45.5 1.5 
9. Japan 38900.6 3816 10.2 83.6 2.4 13.9 1.9 
10. Brazil 8649.9 1357 8.5 45.9 28.5 25.5 1.9 
Table 1
11. Vietnam 2214.4 398 7 53 6.9 37.5 6.2 
12. Mexico 8208.6 1088 6.3 51.17 4.2 44 2.5 
13. Thailand 5910.6 633 4.1 78.7 8.6 12.1 3.2 
14. Myanmar 1195.5 121 2.5 36.2 0 45.6 7.5 
15. Ethiopia 706.8 85 5.5 26.9 0 28.4 7.9 
16. Nigeria 2175.7 225 3.7 22.1 0.8 70.1 1.7 
17. DRC 405.5 46 4.5 21.3 0 37.4 3.8 
18. Korea, 
Republic of 27538.8 2507 7.1 56 6.6 37.4 2.9 
19. Italy 30674.8 3311 9 77.4 0.9 21.7 0.9 
20. Philippines 2951.1 330 4.7 33.6 10.2 54.3 6.8 
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Executive Summary  
 
Viral hepatitis is a major public health threat and a leading cause of death worldwide. Each year 
viral hepatitis kills an estimated 1.4 million people, comparable to other major infectious 
diseases including HIV, tuberculosis, or malaria. 96% of deaths are attributable to hepatitis B 
(HBV) and C (HCV), the focus of this commission. Availability of highly effective prevention 
measures and treatments has made the global elimination of viral hepatitis a realistic goal, 
endorsed by all WHO member states. Ambitious targets have been set out aiming for a global 
reduction in hepatitis related mortality of 65% by 2030 and reduction in new infections by 90%. 
Inclusion of viral hepatitis in the Sustainable Development Goals (SDGs) reflects a recognition of 
the importance of viral hepatitis to development.  
This Commission was formed to take stock of the global situation as we embark on the journey 
to elimination and identifies key interventions needed to accelerate progress. Elimination will 
require comprehensive hepatitis strategies within affected countries and focused action at the 
national and sub-national levels including the intensification of both prevention and treatment 
efforts. Some countries are advancing faster than others. Typically, they have a national 
hepatitis strategy in place and strong political leadership.  
Analysis for this commission finds that 20 countries account for over three quarters of the global 
burden of viral hepatitis. An effective response in these countries is crucial if global elimination 
targets are to be achieved. Home to 10 of the 20 most heavily burdened countries and 
accounting for approximately 70% of viral hepatitis related deaths, the Asian region stands out 
in terms of disease burden and the need for an invigorated response.  
 
The nature of viral hepatitis epidemics differs significantly among countries and responses at 
country level must be context sensitive. In this commission we have sought expertise from all 
affected regions of the world with many examples of success and how to overcome barriers. 
Sharing these experiences will help all to make progress towards elimination.  
 
Vaccination against HBV, which has been a major public health success, is projected to have 
prevented 310 million cases of hepatitis B between 1990 and 2020. Maintaining high childhood 
vaccination coverage rates remains crucial to all elimination plans. The success of HBV 
vaccination of preventing infection in later life means the proportion of new chronic HBV 
infections that arise through mother-to-child transmission is projected to rise from 16% in 1990 
to 50% in 2030.  This makes access to birth dose vaccine a key priority. 
 
Elimination of viral hepatitis will require a shift from an individual patient focus to one that 
emphasizes a coordinated public health approach that includes  interruption of transmission and 
infection through immunization, prevention, and treatment. In the short term, this requires 
designing simplified, standardized packages of interventions that can be delivered at scale. HBV 
and HCV share common transmission routes, and tackling both together can produce better 
*Manuscript
Click here to view linked References
public health outcomes while yielding economic efficiencies. Not only will treating HBV and HCV 
interrupt transmission, it will also help prevent as many as one in 20 of all cancer-related deaths 
worldwide.  
 
The development of public health programmes adapted to national settings is a priority for both 
HBV and HCV and will require education and training programmes, as well as a change in 
regulations, as part of a shift to more decentralised services. Requirements for specialist care 
will need to be minimized, with greater emphasis on less speicalised staff delivering treatment 
and care through task sharing. A policy shift towards treating all individuals with HCV 
irrespective of disease stage, using pan-genotypic regimens, would greatly simplify care delivery 
and has the potential to impact on morbidity, mortality, and transmission. Where possible 
services for managing viral hepatitis should be integrated seamlessly with other related services 
in health systems and many of the interventions required to prevent hepatitis infection should 
form part of efforts to strengthen health systems as a whole and improve safety (e.g. screening 
of transfusion, provision of clean needles, infection control in healthcare facilities).  
 
Perhaps the greatest challenge in achieving elimination targets is scaling up testing to all those 
at risk once treatment is available, as of 2015 an estimated 290 million individuals remained 
undiagnosed. As part of this, there is a need to improve access to appropriate diagnostics that, 
in some settings, are a greater financial barrier to scaling services than drug costs. Inclusion of 
viral hepatitis in WHO’s proposed Essential Diagnostic List is a welcome step forward and pre-
qualification of diagnostics will help with procurement. Research and development funding for 
more affordable, high quality diagnostics suitable for decentralised models of care should 
remain a research priority and health systems must allow for testing to be carried out in non-
hospital settings.  
 
In 2017, more people were infected with HCV than twere cured. In order to reverse this, access 
to quality, affordable treatment needs to be greatly expanded. All originator companies of drugs 
recommended in the WHO Essential Medicines list should develop a clear access plan for lower-
middle-income and upper-middle-income countries. This is not currently the case. Voluntary 
licensing schemes for lower-middle-income countries already achieved substantial price 
reductions in eligible countries, but high-burden upper-middle-income countries unable to 
access such schemes and unable to afford market prices, have become the “squeezed middle” 
until effective access policies are developed or expanded. Key pan-genotypic drugs, particularly 
pibrentasvir and glecaprevir, are not currently available through voluntary licensing. 
Collaboration with the Medicines Patent Pool (MPP) offers one potential avenue to improve 
access. However, in the absence of voluntary licencing, some countries may opt to consider 
compulsory licensing and as an alternatives option 
 
Despite progress in drugs and diagnostics access, financing the elimination of viral hepatitis 
remains a critical challenge and lacks the major global support provided to HIV, TB or malaria. 
With the current emphasis on achieving universal healthcare coverage, countries need to be 
supported in creating “fiscal space” to invest in programmes to eliminate hepatitis. Investment 
plans are needed to support national policies and to ensure evidence informed decision-making 
regarding which interventions will provide the greatest public health returns. In China, for 
example, investing in comprehensive HBV programming is estimated to bring savings of more 
than US $1.5 for each $1 spent, by 2030.  
 
New innovative financing mechanisms may be required to support national programmes. A new 
international body is not essential. Existing international financing and development 
organisations like UNITAID (a leading organization in market shaping focused on HIV co-
infection) are well placed to support expansion of access to prevention, diagnostics, treatment 
for eliminating viral hepatitis and , if domestic efforts to provide funding are unsuccessful, 
identify new streams of finance to support national programmes. 
 
All those engaged with viral hepatitis elimination need quality data and simple, consistent 
targets to monitor progress and advocate for the national prioritisation of viral hepatitis 
prevention and treatment. NGOs and civil society have a key role to play in keeping viral 
hepatitis on the health agenda both nationally and internationally. Coupled with WHO 
monitoring and evaluation efforts and monitoring of the Sustainable Development Goals (SDGs), 
a new scorecard of national progress is needed to ascertain  each country’s progress towards 
elimination of viral hepatitis, which is achievable 
 
 
 
  
Summary Table of Priority areas for action 
 
Priority Area National Priority Actions International Priority 
Actions 
Prioritize investments to 
support countries with 
greatest burden of viral 
hepatitis 
All heavily burdened 
countries to have fully 
funded elimination plans by 
2019 
Recognition of need to focus 
on high burden countries 
and support for national 
policy development  (All) 
Funding for national 
elimination plans 
Creation of fiscal space for 
new programmes with 
costed investment 
programmes 
 
Adopt domestic innovative 
finance tools where 
appropriate 
Support national policy 
makers in their activity 
(WHO, UNITAID, NGOs) 
 
Provide international 
support for financing 
measures (UNITAID, GFATM, 
bilaterial donors) 
Prevention Ensure all WHO elimination 
targets addressed in plans  
 
Address operational 
challenges in delivery of 
birth dose HBV vaccine  
 
Ensure provision of harm 
reduction services and 
engage with marginalised 
group (e.g. prisoners, 
PWIDs).  
 
Ensure clear public health 
messages to encourage 
testing and treatment 
 
Support countries to 
decriminalise injecting drug 
use and ensure equitable 
access to services for all 
(NGOs, WHO, civil society) 
 
Ensure appropriate funding 
for HBV vaccine, including 
birth dose (GAVI, WHO) 
 
Support R&D into HCV 
vaccine development 
(Research funders and 
pharma) 
 
Testing and Models of Care  Focus on substantially 
scaling up testing for HBV 
and HCV 
 
Create and evaluate 
simplified care pathways 
relevant to local setting, 
integrating with existing 
services.  
 
Promote task sharing and 
decentralisation of care 
through capacity building, 
training and removal of 
Support operational research 
into simplified pathways 
(Research funders, UNITAID) 
 
 
requirements for specialised 
prescribing 
Diagnostics Ensure testing is integrated 
into the wider healthcare 
system, rather than 
centralised facilties 
Ensure access to quality 
diagnostics through Essential 
Diagnostic List and pre-
qualification (WHO, funders) 
 
Support implementation 
science for models of care 
and R&D into novel 
diagnostics suitable for 
decentralised settings. 
(Research funders, FIND, 
industry) 
Access to treatment Ensure all Essential 
Medicines for viral hepatitis 
are included in national 
programmes, with an 
emphasis on pan-genotypic 
regimens 
 
Apply comprehensive policy 
approach to promoting 
access, including compulsory 
licensing  
 
 
Ensure all essential 
medicines are pre-qualified 
and either available through 
voluntary licensing or 
Medicines Patent Pool  
(WHO, NGOs, civil society, 
funders) 
 
Support shared procurement 
mechanisms for treatment 
(PAHO) 
Monitor Progress National plans need clearly 
defined, measurable 
objectives 
 
Develop new indices of 
national progress 
Progress of individual 
countries needs to be closely 
monitored towards 
elimination goals (Polaris, 
WHO, Creation of 
Elimination Index) 
 
Develop greater capacity for 
advocacy in high burden 
regions (all) 
 
 
 
 
 
  
Viral hepatitis is one of the leading causes of death in the world. 96% of those deaths are due 
to hepatitis B and C, which are the focus of this commission.  Unlike many other major 
diseases, the tools exist to eliminate viral hepatitis. A highly effective vaccine is available to 
prevent hepatitis B, and a revolution in HCV treatment—namely direct-acting antiviral (DAA) 
drugs—means that therapies are now available that can be provided at scale in high-burden, 
low income countries. The potential to eliminate viral hepatitis has been recognised by recent 
World Health Assembly resolutions. In 2016, the WHO adopted its Global Health Sector 
Strategy setting out ambitious targets for elimination of viral hepatitis as a public health 
problem by 2030, including a 90% reduction in new infections and a 65% reduction in deaths 
attributable to viral hepatitis. At present, only a small number of countries are currently on 
track to meet these targets, but many countries are in the process of developing national 
strategies for the elimination of hepatitis. This commission draws together experts from, 
public health, clinical medicine, civil society, finance and policy to the explore barriers to 
elimination and the means to overcome them. We have drawn on expertise from different 
regions to identify examples of best practice and key challenges ahead. We identify aspects of 
prevention that need to be more widely available and highlight the need for simplified models 
of care to facilitate the scale up of diagnosis and treatment that are required if the WHO 
targets are to be achieved. We also identify means of accessing new treatment and 
diagnostics and potential means to pay for them.  
 
Introduction [H2]  
 
Viral hepatitis is now recognized as a leading cause of death worldwide, causing an estimated 
1·34 million deaths per year (nearly 4,000 per day), rivaling mortality caused by other major 
infectious diseases, including HIV/AIDS, malaria and tuberculosis1. In 2017, WHO released its 
first Global Hepatitis Report, which provided the first-ever baseline estimates of incidence, 
prevalence and mortality from viral hepatitis for the six WHO regions.2 According to the report, 
an estimated 257 million people worldwide were living with HBV infection in 2015 and 71 
million were living with HCV.  
 
Until recently, however, there was a huge disparity between the global burden of disease and 
global policy on viral hepatitis. Viral hepatitis was omitted from the Millennium Development 
Goals;4 before 2008, none of the 8000 WHO employees had ‘hepatitis’ in their job title;5 and no 
non-governmental agencies existed that focused on the plight of people living with viral 
hepatitis worldwide. Thanks in part to data-driven advocacy efforts and the recognition that 
elimination is achievable, viral hepatitis has now cemented its place on the global health agenda 
and is included within the Sustainable Development Goals (SDG 3).  
 
In 2016, WHO adopted its Global Health Sector Strategy (GHSS) for viral hepatitis,2 which 
outlines an ambitious agenda for the global elimination of viral hepatitis as a public health 
threat by 2030, including a roadmap towards elimination and key prevention and treatment 
interventions aimed to strengthen health systems within the context of the universal health 
coverage framework.  
 
To achieve the WHO target for elimination of viral hepatitis—namely a 90% reduction in new 
infections and a 65% reduction in deaths attributable to viral hepatitis by 2030--efforts need to 
be sustained amidst a global health agenda that is increasingly focused on health systems 
approaches and non-communicable diseases rather than disease-specific programmes and 
communicable diseases. For this reason, a unified response to viral hepatitis is warranted, rather 
than siloed programmes for individual viruses. Viral hepatitis is infectious in nature, but with 
long-term sequelae including cirrhosis and hepatocellular cancer, it spans the divide between 
communicable and non-communicable diseases. HBV and HCV are responsible for more than 
50% of all cases of liver cancer, which is the third biggest cancer killer globally and the second 
biggest in Africa3,4   Elimination of viral hepatitis has the potential to prevent more than one in 20 
of all cancer deaths globally3. 
 
The commission aims to identify the key challenges in achieving elimination when developing 
strategies for viral hepatitis elimination, and in doing so has drawn on a wide range of expertise. 
Our audience includes those involved in advocating for and developing those strategies. We also 
identify areas in which greater innovation—in technology, service delivery and finance—will 
help drive efforts towards elimination. In this section, we present an overview of current 
progress in tackling hepatitis B and C. In section 2 we review proven strategies for prevention of 
viral hepatitis and the priorities for implementation. Section 3 addresses some challenges of 
diagnosis, models of care and the need to improve access to affordable diagnostics. Access to 
medicines and the need for innovative financing strategies are outlines in Section 4. There is no 
large source of external funds for hepatitis, akin to the Global Fund for HIV, TB and malaria 
(GFATM), and unless the GFATM is able to extend its remit, hepatitis needs to be prioritised 
within domestic health funding. For many countries this is likely to require innovative means of 
financing.  
 
This commission comes at a time when an increasing number of countries are beginning to 
develop viral hepatitis elimination strategies. Whilst there are shared issues among these 
countries, there are also issues of specific importance to different regions and different 
countries. In section 5, we have drawn together experts from different regions to identify 
examples of progress and regional barriers to elimination. In contrast to other work, we have 
taken a perspective of disease burden, drawing on analysis of the Global Burden of Disease 
programme to identify key priority countries.  
 
The global burden of viral hepatitis and need for high quality data [H2] 
 
In 2016, more than 75% of the global burden of hepatitis and its related diseases was 
shouldered by only 20 countries (figure 1). To achieve meaningful progress towards the WHO 
targets for elimination will require a particular focus on progress within these countries, half of 
which are in Asia, the region with by far the greatest burden of disease. Strikingly, only two of 
the most heavily burdened countries—USA and Japan—have made progress in reducing the 
burden of viral hepatitis in the last 20 years (supplemental figure 1). The majority of the 20 most 
heavily burdened countries are low-income or lower-middle-income, highlighting the need to 
help develop strategies that are achievable in healthcare systems with substantial financial and 
infrastructure constraints. 
 
The WHO targets for progress towards elimination identify key areas in the coverage of services 
for those infected with hepatitis B and C (figure 2) Achieving progress in these areas requires 
further scale-up of interventions proven to be effective for both prevention, diagnosis and 
treatment, and of access to medicines.  
Accurate surveillance data for new infections, chronic infections and mortality alongside 
programme monitoring indicators will be required not just to monitor progress toward 
elimination but to justify the investments required. In 2017, WHO released its first viral hepatitis 
report, which provided the first baseline estimates of the 10 core indicators of the Global Health 
Sector Strategy on viral hepatitis for the six WHO regions  (figure 2) 1. However, many gaps exist 
in data quantity and quality, and a critical review of the uncertainty of these estimates is 
required for countries to establish better systems for the generation of data that can guide 
elimination efforts.  
 
Incidence, prevalence and mortality [H3] 
 
Estimates of the incidence of HBV and HCV infection come from different data sources. For HBV, 
the proportion of children aged five years who are chronically infected is used a surrogate 
indicator of the cumulative incidence of chronic HBV infection in the first five years of life, as a 
majority of infections are acquired in this time frame. It is also monitored as an indicator of 
progress towards the Sustainability Development Goals. For HCV, data are more limited, and 
most incidence estimates derive from mathematical models that are based on prevalence data. 
Generating better data, particularly on HCV incidence, will be increasingly important as efforts 
to scale up treatment progress.  
 
Estimates of new infection with HBV have fallen steadily, from a peak of over 18m new 
infections per year in the early 1990s to an estimated 4.7m new infections in 2015, due to the 
introduction of the HBV vaccine 5. New HBV infections are predicted to remain close to 3 million 
a year by 2030 without further scale up of prevention and treatment 5 (figure 3).  In 2015, WHO 
estimated that 1.3% of children under five worldwide were positive for hepatitis B surface 
antigen (HBsAg), ranging from 4.7% in the African region and 0.3% in the Americas region. The 
prevalence of HBsAg in children is assessed with surveys to measure the impact of universal 
hepatitis B immunisation of infants. However, many countries have not conducted such surveys, 
and estimates require extrapolation from countries with better quality data. In the WHO 
Western Pacific region, where HBV prevalence was very high in the pre-vaccine era, a regional 
initiative strongly encouraged countries to conduct surveys after vaccine introduction 6. As a 
result, the uncertainty interval around the 0.9% prevalence estimate for this region is relatively 
narrow (95% uncertainty interval 0.6%—1.3%), whereas uncertainty intervals are wider in 
regions such as Africa (3% [2.0%—4.7%]), where fewer surveys have been conducted. Better 
data from Sub-Saharan Africa are needed to estimate the impact of the 76% coverage of the 
three-dose vaccine in the absence of a timely birth dose policy in most countries in this region. 
 
Measuring the incidence of HCV infections is challenging in the absence of a test for recent HCV 
infection and in view of the high frequency of asymptomatic infections. Modelling estimates 
suggest that worldwide, in 2015, there were 1.75 million new HCV infections (global incidence 
rate of 23.7 per 100 000; uncertainty interval 1.6-2.1)1. The incidence of HCV infection may be 
estimated using several methods, including back-calculation from a curve with the age-specific 
prevalence of HCV infection, inference from sequential biomarkers surveys, and modelling 
based on estimates of the incidence of infection in various risk groups.  Such modelling poses 
several methodological challenges, including difficulty in estimating incidence in regions where 
incidence is low or when input data on age-specific prevalence is of poor quality or is 
unavailable, and the necessity of assuming static prevalence data for inferring incidence 
estimates, which may not be appropriate in some countries, particularly as treatment and 
prevention are scaled up.  
 
Trends in incidence identified by modelling studies can be verified using surveillance data, but 
these data also have limitations. Data on reported cases of acute HCV can provide information 
on time trends but are limited by substantial underreporting and a large proportion of 
asymptomatic infections. Data from longitudinal cohorts of at-risk populations, such as people 
who inject drugs (PWID), provide valuable information about changes in incidence over time and 
the impact of treatment scale up, but they can be difficult to obtain.  
 
In 2015, WHO estimated that 257m people (3.5% of the population; uncertainty interval 199-
368m) were living with HBV infection and that 71m people (1% of the population; uncertainty 
interval 62-79m) were living with HCV infection (figure 2, 4) 1. The change from reporting 
prevalence based on individuals with detectable anti-HCV antibodies to only those with active 
HCV infection (based on detection of HCV RNA) is an important reflection of the high proportion 
of antibody-positive individuals who do not require treatment. HCV prevalence estimates are 
based on data from systematic reviews and extrapolations for areas of the world that do not 
have data. Biomarker surveys estimating the prevalence of HBsAg or antibodies to hepatitis C 
are the reference methods more commonly used to measure the prevalence of HBV and HCV 
infections. Countries that have a high burden of disease because of high prevalence, such as 
China,11 tend to conduct such surveys to guide their policies. In countries that have lower 
endemicity, the costs of biomarker surveys are harder to justify and data are of lower quality, 
leading to more uncertainty. Even in countries in which biomarker surveys are conducted, the 
data are often limited by non-representative sampling strategies, issues with quality assurance 
of diagnostic assays, and absence of data disaggregated by age groups. 
 WHO estimated that viral hepatitis was responsible for 1.34 million deaths in 2015 1. These 
estimates are based on a combination of data from vital registration databases (national data 
routinely collected on deaths), models that quantify the number of deaths from cirrhosis and 
hepatocellular carcinoma, and data from studies reporting the fraction of cirrhosis and 
hepatocellular carcinoma that are attributable to HBV and HCV infections7,8. As such, estimates 
of mortality attributable to HCV and HBV vary depending on the data source9. Improving and 
harmonising all estimates relevant to elimination is a priority for ongoing work which can be 
supported by all those involved in patient care, ensuring, for example, that causes of death are 
recorded and reported as accurately as possible. Increasing co-ordination between key 
organisations should continue improve the consistency and reliability of estimates, one 
important example being the announcement of greater collaboration between the Institute of 
Health Metrics and Evaluation, IHME and the WHO10. 
 
 
 
 
 
 
 
 
Figure 1 Total Disability Adjusted Life Years (DALYs) to hepatitis B and C in in 20 most heavily 
burdened countries, both sexes, all ages, derived for this commission from Global Burden of 
Disease dataset (2016) 
 
 
 
 
  
 Figure 2. Baseline estimates (2015) of progress towards elimination targets 
 
   
Figure 3 Estimated total number of new chronic carriers of HBV infection annually with current 
levels of intervention (adapted from5) 
 
  
Figure 4 (a) Estimated numbers of viraemic HCV-infected individuals 2015 and (b) Estimates for 
HBsAg prevalence for countries with data and a model, or for which data were extrapolated 
from countries in the same GBD region with available data (all ages)11,12 
 
 
 
 
 
 
  
Prevention of Viral Hepatitis [H2] 
 
The shared routes of transmission for hepatitis B and C viruses and HIV—through percutaneous 
or mucosal exposure to infected blood and bodily fluids—confers advantages in streamlining 
viral hepatitis prevention efforts, with a focus on integrated responses rather than vertical 
programmes.   
 
The HBV and HCV epidemics vary considerably in different geographical settings, with different 
risk groups and risk factors for infection; thus, it is important that public health officials identify 
an appropriate mix of interventions that are adapted to the epidemiologic situation in a specific 
country.  For example, in many high-prevalence countries, most HBV infections occur among 
children, whereas in low prevalence areas, more infections occur among adults, usually in 
defined populations 13. Similarly, in high-income countries, most HCV transmission occurs among 
PWID, whereas in many middle and low-income countries, where infection prevention and 
control measures are weak, a large proportion of new infections occur in the health-care 
settings through unsafe injections and other invasive procedures 14. Although there are 
substantial regional differences, globally the biggest gaps in service coverage relate to 
prevention of mother-to-child transmission of HBV and provision of harm reduction services 
among PWID. 
 
Preventing early-life infection [H3] 
 
Globally, most hepatitis B infections occur around the time of birth through exposure to 
maternal blood and secretions, and in the first years of life through horizontal transmission 
among household contacts 15. The risk of mother-to-child transmission ranges from 5% for 
women without detectable circulating concentrations of HBV E antigen (HBVeAg; a marker for 
high viral load) to 90% for women with detectable HBVeAg. The approaches to preventing early-
life HBV infection can be broadly categorised as those administered to all children and those 
administered only to children born to mothers with chronic HBV infection (figure 3)  
 
Horizontal transmission of HBV infection can be prevented by administration of HBV vaccine in 
early life, with three doses of vaccine shown to provide lifelong protection in more than 90% of 
individuals 16. WHO recommends that all children be vaccinated against HBV within 24h of birth 
(a single antigen vaccine known as the birth dose vaccine), with two or three additional 
vaccinations with a heptavalent vaccine given starting at six weeks of age 16. As of 2015, 
universal childhood vaccination has being implemented in 185 countries, and 84% of children 
born in 2015 were vaccinated with three doses of heptavalent HBV vaccine 17. The global scale-
up of hepatitis B vaccination has produced dramatic results, most notably in the Western Pacific 
region, where HBV immunisation has averted an estimated seven million deaths that would 
otherwise have occurred in the lifetime of children born between 1990 and 2014 18. Globally, 
existing interventions are estimated to have reduced the incidence of new HBV infection by 
83%, thus preventing 310 million chronic infections that would otherwise have occurred 
between 1990 and 2020 5.  In Taiwan, universal HBV vaccination, which was implemented in 
1984 and has high coverage rates, has reduced chronic liver disease and HCC-associated 
mortality by 90% among children and young adults who were vaccinated compared to those not 
vaccinated 19.  
 
The birth dose vaccine is the simplest and most effective means of preventing mother-to-child 
transmission of HBV infection and is the only strategy recommended by WHO. Progress in 
adopting the birth dose vaccine has been slower compared with childhood vaccination. Only 97 
countries include it in their routine immunisation schedules, and only an estimated 39% of 
children received the birth dose in 2015 17. Reasons for the low coverage of birth dose 
vaccination include lack of national policies, insufficient awareness among health care workers, 
high proportions of births occurring at home in some countries, and lack of coordination 
between vaccination and maternal-health programs. An additional barrier is financial, as donor 
agencies such as GAVI purchase the heptavalent childhood vaccine but not the single-antigen 
birth dose.  
 
HBV transmission can still occur despite administration of the full vaccine schedule, particularly 
from women with high HBV viral loads. Therefore, in many countries with higher resource levels, 
additional measures are recommended for women at higher risk (figure 5), including 
administration of hyper-immune hepatitis B immunoglobulin (HBIg) in pregnant women who 
test positive for HBsAg, and treatment with antiviral drugs such as tenofovir for pregnant 
women with high HBV viral loads (ie, > 200,000 IU/mL), who are at particularly high risk of 
transmitting the virus 20. Because of logistical challenges associated with HBIg administration 
and antiviral therapy, these interventions are not currently recommended by WHO.  
 
A key question is what interventions should be prioritised and what additional measures are 
needed to eliminate early-life HBV infection (supplemental figure 2). Maintaining high rates of 
childhood vaccination is critical, but as the prevalence of HBV infection declines as a result, the 
proportion of perinatal infections will increase. Indeed, the proportion of new chronic infections 
that arise through mother-to-child transmission is estimated to increase from 16% in 1990 to 
50% in 2030 5. Therefore, in most regions, additional interventions will be required to further 
reduce infection rates. Scaling up childhood vaccination to 90% globally has been estimated to 
prevent 4.3 million HBV infections between 2015-2030 (figure 3) scaling up birth-dose 
vaccination coverage to 80% would prevent approximately 18.7 million HBV infections in the 
same time period 5. 
 
Progress in childhood HBV immunisation has slowed, and global vaccine coverage has increased 
by only 1% since 2010 21,22. By 2015, only 126 of 194 countries had achieved the WHO target of 
90% coverage of the third dose of HBV vaccine, and in only 52 of these countries did coverage 
exceed 80% in all districts 22.   
 
Clearly, the main priority to reaching elimination goals is to identify strategies to increase the 
administration of birth dose vaccine while also improve coverage rates of childhood vaccination. 
WHO’s Strategic Advisory Group of Experts (SAGE) has made recommendations for 
strengthening national vaccine programs, including advocating for stronger national leadership 
and commitment, securing investments, and enhancing surveillance and accountability 
mechanisms 22.  For birth dose vaccination, international health agencies should continue to 
advocate alongside national governments for the inclusion of the birth dose vaccine in national 
vaccine schedules. In the absence of donor funding for the procurement of birth dose vaccine, it 
is important that national governments allocate sufficient funds to purchase the vaccine. As 
recommended by WHO, health-system interventions are also needed 23. The most direct way to 
improve birth-dose coverage is to promote childbirth within health facility and strengthen 
linkages between immunisation and maternal-child health programs to ensure availability of 
vaccine and to promote awareness among health care workers. For children born at home, 
providing HBV birth dose to birth attendants and community health workers should be 
promoted as a way of reaching newborns who do not have contact with clinics around the time 
of birth. Structural interventions, such as simplified injection mechanisms and utilisation of 
vaccine that does not require cold-chain storage could also help improve birth-dose vaccine 
coverage 23.  
 
To fully minimise the risk of perinatal transmission, antenatal screening is important to identify 
women with chronic HBV infection, particularly those with high viral loads, provided the 
necessary resources (including appropriate diagnostics) are available. Many countries, including 
Africa, conduct universal antenatal HIV testing, and serologic testing for HBV could be 
incorporated into this testing with little additional cost. Since access to viral load testing is 
limited, a potential option is to administer antiviral drugs to all pregnant women who test 
positive for HBsAg, but the potential benefit and feasibility of this approach requires further 
study. Low-income countries should prioritise birth dose and routine childhood vaccination.  
 
Mother-to-child transmission of HCV is not a major route of infection, with an estimated risk of 
5.8% (95% CI, 4.2%–7.8%) among HIV-uninfected women and 10.8% (95% CI, 7.6%–15.2%) 
among women with HIV infection 24. Nevertheless, as HCV infections through other routes of 
transmission are reduced, mother-to-child transmission might account for a higher proportion 
of new infections. DAAs, which rapidly reduce HCV viral load and cure HCV infection in a 
majority of people, are not yet approved for use in pregnant women, and studies are needed to 
determine their safety in this population. Since HCV therapy is curative, identifying and treating 
women with HCV infection before they become pregnant is currently the best approach to 
reduce this route of transmission and to improve the health status of these women.  
Preventing infection amongst high risk adults [H3]  
 
People who inject drugs [H4] 
PWIDs are at high risk of hepatitis infection, and increased efforts to prevent transmission in this 
population will be essential to meet the global targets on elimination. Injection drug use has 
been reported in at least 179 of the world’s countries and territories, 25 and according to the 
most recent estimates, there are currently 15∙6 million (95% uncertainty interval 10∙2–23∙7 
million) PWID aged 15–64 years globally 26. However, these figures underestimate the true 
prevalence of injection drug use because this practice is often under-reported because it is 
stigmatised and often illegal  27.   
 
The sharing of injecting equipment (principally needles and syringes but also other 
paraphernalia) is a major risk factor for the transmission of viral hepatitis, particularly HCV 28.  As 
a consequence, 52∙3% (95% UI 42∙4–62·1) of PWID are HCV-antibody positive, and 9∙1% (95%UI 
5·1–13·2) are HBsAg positive 26. Worldwide, the prevalence of HCV infection among PWID is 33-
fold higher, and of HBV is 2.5-fold higher, than in the general population 29,30. Further, PWID are 
estimated to contribute to nearly 40% of Disability- Adjusted Life-Years (DALYs) due to HCV and 
1% of DALYs due to HBV 31.  
 
Implementation of a comprehensive package of harm reduction services for PWID is one of the 
priority actions outlined in the GHSS 32. The package includes needle and syringe programmes 
(NSP), opioid substitution therapy (OST), hepatitis B vaccination, information, education and 
communication in risk reduction, and diagnosis and treatment of chronic hepatitis infection 33.  
WHO also recommends the use of low-dead space syringes (to reduce the transmission of virus 
when needles are shared) and the offer of peer interventions among PWID 34. 
 
For HBV, targeted vaccination with the rapid schedule is recommended for PWID, including in 
countries that have the HBV vaccine incorporated into national childhood immunisation 
schedules 35. However, vaccination rates have been poor in this population. Improving 
convenient access to vaccine (eg in prisons, NSP, and drug treatment centres) and offering 
incentives have been shown to increase HBV vaccine coverage among PWID 35.  
 
There is considerable evidence to support the effectiveness of both NSP and OST in reducing 
injecting risk behaviour and hepatitis virus transmission among PWID with the biggest individual 
risk reductions (70-80%) reported using a combination of NSP and OST 36-39. However, despite 
multiple guidelines recommending NSP and OST, and widespread endorsement from 
international agencies, the global response continues to be woefully inadequate 40,41. For 
example, there is still no provision of NSP and OST in 52% and 48%, respectively, of the 179 
countries where injection drug use has been reported 25. A major barrier to properly addressing 
the transmission of hepatitis viruses among PWID are national drug policies that prioritise 
criminalisation of drug use and drug suppression. Even in countries where harm-reduction 
services are authorised, police practices of harassment and arrest of PWID attending NSP and 
OST distribution centres limits their availability and effectiveness. As outlined in the Lancet 
commission on public health and international drug policy 42, national drug policies should be 
modified to decriminalise minor drug offences, allow the possession of syringes, and ensure 
equitable access to harm-reduction services, including to marginalised groups such as prisoners 
42. Once appropriate policies are in place, harm-reduction programs need to be sufficiently 
financed and designed so that they are accessible and acceptable to PWID, responsive to their 
needs, and free from the threat of harassment and arrest. Securing political commitment, 
investment in advocacy and, where necessary, revision of laws, legal policies and practices are 
critical to establish a more supportive environment 33.  
 
In addition to improving access to harm-reduction services, a comprehensive approach to 
hepatitis control must include access to HCV therapy for PWID who are infected. Accumulating 
evidence shows that PWID can achieve HCV cure rates similar to non-PWID, although re-
infection rates are higher 43-46.  Treating PWID wii also reduce risk of transmission, which would 
contribute to lowered prevalence 47-49. Despite this, access to treatment is low among PWID, in 
part because HCV drug eligibility policies exclude active injectors in some countries. 
Furthermore, many health-care providers are reluctant to prescribe HCV therapy to PWID 
because of concerns of low adherence to treatment regimens. Educational efforts are needed 
among providers to highlight the importance of treating hepatitis among PWID. Economic 
evaluations suggest that, in many settings (where prevalence of chronic HCV infection is ≤40%), 
treating PWID early with DAA regimens is more cost-effective than treating other patient groups 
because of the potential additional benefit of averted transmissions 50 Further, national models 
of HCV elimination–such as that in Georgia–suggest that targeting and prioritising PWID for HCV 
therapy is critical for reducing transmission in the population as a whole. However, in many 
countries, HCV treatment is unavailable for people with mild disease or for PWID who are not in 
long term OST. Thus, empirical evidence demonstrating that treatment can indeed prevent 
transmission of HCV in PWID populations remains key to strengthening international guidelines 
and driving change in clinical practice 51-53.  
 
Prison populations [H4] 
 
Incarcerated individuals are exposed to a unique environment in which various combinations of 
risk factors are ubiquitous, such as injection drug use, high-risk sexual activities, tattooing, and 
sharing of utensils, razors and nail clippers. The risk among inmates is further exacerbated by 
poor living conditions, such as overcrowding and poor hygiene 54-56. The prevalence of HBV and 
HCV infections is higher in prisons compared with the general population, with the prevalence in 
the different regions of the world ranging from 1.4%-23.5% for HBV and 1.8%-20.6% for HCV 57. 
Incidence of HCV among prisoners is also high, reported to be up to 30 cases per 100 prisoners 
per year 58,59.  
 
In most countries, enforcement of strict drug laws results in overrepresentation of PWID in 
penitentiary systems 56. Approximately half of the prison population in the European Union has 
ever used illicit drugs.  The time immediately following release from prison is also a period 
marked by increased sexual and drug use risk behaviours, which could lead to transmission of 
HBV, HCV, and HIV 60. 
 
Most prisoners do not have access to recommended intervention services aimed to reduce the 
risk of infection; for example, only eight countries have implemented NSPs in at least one prison 
61. This low level of services is due in large part to the fact that medical services in prisons are 
administered by the criminal justice system, whose priorities differ to that of the public health 
system. This is further exacerbated by low levels of investment in medical infrastructure and 
human resources for health in the prison systems.  
 
Reducing the risk of hepatitis infection among prisoners will require high-level coordination 
between national health and criminal justice authorities, which would facilitate the 
development of prison-health policies and programs that were aligned with public-health 
priorities.  
 
Promoting multi-stakeholder engagement with advocacy groups, peer-educators, academics 
and the general community would further help in the alignment of prison-health and 
community services. In addition to policies, greater investment is needed in the prison-health 
system to address insufficiencies in medical staffing and education as well as funding the 
provision of prevention and treatment services (including in the post-treatment phase).  
 
In addition to enhancing prevention programs in prisons, treatment needs to be more widely 
accessible. With the duration of HCV treatment now as short as eight weeks, completion of HCV 
treatment is feasible in prison settings, even with short sentences. Because one of the obstacles 
for antiviral treatment in prisons is low awareness of infection status, the role screening for HBV 
and HCV upon entry and regular testing during the period of incarceration is something that 
needs greater evaluation to identify those needing antiviral treatment. 
 
Sexual transmission and men who have sex with men [H4] 
 
Sexual transmission occurs for both HBV and HCV and is thought to be the main route of 
transmission of HBV among adults; approximately one quarter of sexual partners of persons 
with acute HBV will become infected within six months 62. Compared to the general population, 
sex workers, persons with multiple sex partners, and men who have sex with men (MSM) have 
increased prevalence of HBV infection 63. The HBV vaccine effectively protects against sexually 
acquired HBV infection, and existing guidelines recommend that persons at increased risk of 
sexually transmitted infection be vaccinated 16. Despite this, vaccine coverage remains low 
among adults in these populations 64,65, and health care providers often do not offer HBV 
vaccine to them 66. Implementing strategies to improve coverage of HBV vaccination among 
individuals at increased risk of sexual transmission is a priority. This can be achieved by targeted 
vaccination, for example, at health facilities providing sexual health services or general-
population approaches such as catch-up vaccination campaigns for school-age children to 
provide protection for those who were not vaccinated as infants.  Strategies to address risky 
behaviours, such as education efforts to promote condom use and partner reduction remain 
important interventions to prevent sexual transmission of hepatitis viruses. 
 
Sexual transmission of HCV is less efficient than that of HBV. MSM with HIV infection are at the 
highest risk of sexual transmission of HCV;I incidence of HCV is high in this population and has 
increased in recent years, particularly in Europe 67.  According to one review, MSM with HIV 
were at 4.1 time higher risk of acquiring HCV infection (6.08/1000 PY [95% CI 5.18-6.99]) than 
were MSM without HIV infection 68. The strategies to reduce sexual transmission of HCV are the 
same as HBV transmission. Although a unique concern is the high rate of HCV reinfection in this 
population 69, early empiric data from populations such as the Netherlands suggest a major 
impact on new infections once DAA treatment is widely available 70. 
 
Healthcare associated transmission [H3] 
 
Since HBV and HCV are transmitted through exposure to blood and bodily fluids, they are readily 
transmitted in health-care settings. Health-care associated HBV and HCV infections occur 
through blood transfusions, unsafe injections and other invasive medical procedures. There are 
no reliable estimates for the importance of transfusions as a source of hepatitis infections, but 
transfusion-associated infections are easily preventable by screening all blood donations in a 
quality-assured manner. According to WHO data, in 2013, 97% of 137 countries with available 
information were screening all blood donations using basic quality procedures, which included 
documented standard operating procedures and participation in an external quality assurance 
scheme 71. However, screening of blood units is only one component of a well-functioning blood 
transfusion service. Other components include recruiting and retaining safe, voluntary, non-
remunerated donors and appropriate clinical use of blood to reduce unnecessary blood 
transfusions. Reliable access to quality-assured test kits also remains a problem 72. Improved 
program monitoring systems that collect data on testing practices in blood banks would provide 
useful information on how to strengthen national blood-safety systems.  
 
According to modelling studies, in 2010, health care injections accounted for approximately 
315,000 HCV and 1.7 million HBV infections 73. Between 2000 and 2010, there was an 83% and 
91% reduction in the number of injection-associated HBV and HCV infections, respectively, 
primarily as a result of increased use of single-use syringes and needles 74. Despite this progress, 
unsafe injections remain an important source of hepatitis infection in certain parts countries, 
most notably the Eastern Mediterranean region where medical injections are overused and 
delivered in the informal health sector where it is difficult to enforce infection control practices.  
 
National policies for the safe and appropriate use of injection must be based upon a three-prong 
approach 75 that includes a behaviour change strategy among patients and health care workers 
to reduce injection overuse and achieve safety; provision of sufficient quantities of injection 
devices and infection control supplies (include auto-disable syringes, reuse-prevention devices 
and sharps injury prevention devices); and safe sharps waste management. In 2015, WHO issued 
guidelines recommending the exclusive use of re-use prevention devices 76. Introduction of such 
devices will be key in countries where unsafe injections continue to fuel the HCV epidemic 
77.Injection safety activities must include interventions to prevent needle-stick injuries and 
implementation of universal precautions, routine HBV immunisation, provision of personal 
protective equipment and post-exposure management. A core component of an infection 
prevention and control (IPC) program is a reliable monitoring system that can assess the 
comprehensiveness, quality, and impact of IPC interventions. This can be challenging because of 
the wide range of recommended interventions and because some indicators require special 
surveys 78  
Hepatitis C vaccine 
 
A vaccine that could effectively prevent HCV infection would be an important tool to help 
control the HCV pandemic, particularly for groups experiencing high rates of HCV infection and 
re-infection. Even with high coverage of DAAs, a partially effective vaccine could have an impact 
in reducing HCV prevalence among PWID 79. Unfortunately, the prospects for having such a 
vaccine remains distant. HCV vaccine development is made difficult by the number of distinct 
genotypes, the high mutation rate of HCV, the lack of an animal model and increasing challenges 
in undertaking efficacy studies  80.  Several candidate vaccines are in Phase I or II trial and 
although it will be many years before these vaccines could potentially be ready for use, they 
should remain a priority for the long-term elimination of infection.  
 
  
Panel 1: Priorities for prevention for national and international policy makers 
 Early-life HBV infection 
o Promote global efforts to increase coverage of universal childhood vaccines 
(including HBV) 
o Promote introduction of birth-dose vaccination into national vaccine policies 
(and carry out operational research into how it is best delivered) 
o Advocate for budgeting and procurement of birth dose vaccine by international 
agencies, including Gavi, and national ministries of health 
o Evaluate novel vaccine technologies that support community based delivery  of 
HBV birth dose vaccine and prenatal antiviral administration in resource limited 
settings  
 Prevention among PWID 
o Promote decriminalisation of drug use and engagement of services with PWID  
o Increase coverage of harm reduction services through provision of OST and 
needle exchange 
o Expand provision of HCV treatment services among PWID 
 Prevention among prisoners 
o Make health intervention in prisons a priority 
o Expand provision of hepatitis testing and treatment services among prisoners 
 Prevention of infection in the general population  
o Promote hepatitis B vaccination and risk reduction interventions among persons 
at increased risk of sexual transmission of hepatitis 
o Increase awareness among health care workers and general population about 
overuse of medical injections 
o Introduce reuse prevention syringes 
o Strengthen infection prevention and control efforts 
o Strengthen blood-transfusion services to improve quality assured testing of 
blood donations 
  
Screening, diagnosis, cascade of care [H2]  
 
Screening and diagnosis [H3] 
 
Timely testing is a critical public health intervention for disease prevention through early 
detection and treatment, particularly for chronic infections such as HBV or HCV that can have a 
long asymptomatic phase. For viral hepatitis, insufficient testing and linkage to care, rather than 
access to drugs, is an increasing barrier to elimination efforts. In 2017, only 9% of the estimated 
257 million people with chronic HBV infection and 20% of the 71 million with chronic HCV 
infection were estimated to have been diagnosed1, illustrating the urgent need for improvement 
and scale up of testing strategies. There are wide disparities between regions in the reported 
proportion of infected individuals who are diagnosed (eg, for HBV, the proportion diagnosed is 
estimated at 83% for South Korea compared to 2% and 3% for India and Pakistan, respectively. 
However, it needs to be recognised that in many high burden countries, such as India and China, 
testing is common outside of the public health system where quality of tests is variable and data 
is not well captured in routine practice.   
 
Achieving the high levels of diagnosis needed to reach elimination targets requires countries to 
incorporate testing and screening strategies into their national plans, with approaches tailored 
to the epidemiology, health priorities and health care resources of each region. The costs of 
testing receive less attention than drug costs, and work for this commission has demonstrated a 
strong correlation between gross national income (GNI) and proportion of individuals diagnosed 
with hepatitis C (supplemental figure 3). The main approaches are general population screening 
and a targeted risk-based screening of key populations. Targeted risk-based testing for HBV and 
HCV should be universally adopted given its higher yield and intuitive sense; however poor 
recognition of risk factors or identification of key at-risk populations in certain regions might 
necessitate the inclusion of general population screening approaches.  
 
Compared to HIV infection or non-communicable diseases, HBV is particularly appealing for 
mass adult screening in highly endemic settings. A single screening in adulthood should be 
sufficient to identify infected individuals given that infection is usually acquired early in life and 
those not chronically infected are likely to have protective immunity due to childhood exposure. 
Few studies of the feasibility and cost-effectiveness of population-based screening for viral 
hepatitis have been done in high-burden, low-resource settings, but studies in The Gambia81,82 
suggest that population-based testing improves linkage to care and can be cost-effective. 
Community sensitisation and patient support groups are critical to the success of introducing 
viral hepatitis screening programmes either in the general population or at-risk groups. 
 
For HCV, in countries where falling drug costs have allowed rapid scale up and cure of patients 
engaged in care, the focus has quickly turned to the challenge of identifying undiagnosed 
individuals. Broader testing approaches can be fruitful in this context. For example, Egypt has 
begun to screen army recruits, university students, and hospitalised inpatients, in an effort to 
identify the still sizable population of undiagnosed individuals. In high-income countries, 
population screening has focused on specific populations, such as the 1945-65 birth cohort in 
the USA, and adult men up to age 60 and prenatal women in France83. While these approaches 
have been shown to be cost-effective, implementation has been challenging, and when used in 
isolation, these approaches may miss a significant proportion of those infected83. 
 
Scaling up testing to achieve the diagnosis rates required for elimination may be possible 
without widespread population testing. Targeted screening approaches need to focus on high-
risk groups, including PWID, individuals who are incarcerated and MSM, with universal screening 
offered in relevant settings such as prisons, supervised injecting centres, homeless or migrant 
centres, or opioid substitution centres. Modelling suggests that in a number of these high-risk 
populations, frequent (eg, annual) testing is required to reduce transmission and achieve WHO 
elimination targets84. However, there are relatively little data on the cost-effectiveness of 
different testing approaches, particularly in LICs85 where such work needs to be given higher 
priority.  
 
Facility-based screening of symptomatic individuals, including those with cirrhosis, offers an 
alternative approach. In Egypt, this strategy led to thousands of people with HCV being 
identified and treated over a short period of time.86 However, whilst relatively simple to initiate, 
the economic considerations of such a strategy have been poorly assessed in LICs and LMICs. For 
HCV, such an approach is likely to have minimal impact on the on-going transmission of infection 
in the population, given that a large proportion of newly infected individuals have mild disease 
50. There has been a suggestion that testing strategies could be mandated by the state as a 
requirement for accessing services (eg, visas, driving licences and marriage licences). In theory, 
this approach could also be extended to provide evidence of successful treatment. However, 
adoption of such approaches has not been widespread due to human rights concerns.  
 
The commissioners recognise that a staged, pragmatic, approach to screening may be necessary 
to achieve the high levels of diagnosis needed to achieve elimination. Countries may prioritise 
systematic screening in health facilities (eg, pregnant women and those attending liver services) 
and secure access to drugs and diagnostics initially. Screening can then be scaled up to at-risk 
groups and finally extended to population-based screening where required. 
 
Cascade of care and models of care [H3] 
 
The cascade of care for the management of HBV and HCV has historically had major gaps, 
starting with low rates of diagnosis that ultimately lead to low treatment uptake and cure or 
control of disease. With the development of highly effective and safe therapies, many assumed 
that the cascade of care would rapidly improve and that a majority of infected individuals would 
be treated and, ideally, cured.  However, many of the gaps in care occur long before treatment 
is considered (figure 7). As such, interventions to increase diagnosis rates, linkage to care and 
retention in care will be required to make significant progress toward the elimination of viral 
hepatitis.   
 
Scaling up of care services for both HBV and HCV in high burden, low-income settings can be 
accelerated by learning from the management other infections. In particular, access to care will 
be limited if confined to speciality-based models of care (eg, requiring hepatologists, infection 
specialists or other skilled and expensive healthcare workers). Task sharing, in which a less 
specialised workforce is trained to deliver care, has not been widely adopted in high-income 
countries but has been an important part of treatment programs for HIV, TB and malaria in low-
income settings, and could be equally beneficial in the context of viral hepatitis.  
 
Models of care for HCV and HBV are different, primarily because of the lack of curative 
treatment strategies for HBV. As such, HBV care is focused on long-term disease monitoring and 
viral suppression (similar to HIV care), whereas HCV treatment is relatively short-term, 
particularly in those without advanced liver disease (similar to tuberculosis care). However, for 
individuals with HCV, longer-term care might be required to monitor for reinfection and 
complications of fibrosis. Innovative models of care will be needed to engage and maintain 
people in care, particularly for populations with less access to or engagement with the 
healthcare system.  
 
Cascade of care and improving care models for HCV [H4] 
 
There are many gaps in the cascade of care for individuals with HCV, including initiation of care 
(lack of diagnosis), retention in care, initiation of treatment after diagnosis, and screening for 
complications including liver fibrosis and HCC. Initiation of treatment is often hampered by 
restrictions on eligibility of DAA prescribers, which is often limited to specialist settings, and 
might particularly impact individuals in rural or remote areas with limited coverage by 
specialists.87  
 
These restrictions also disproportionately affect high-risk individuals, such as PWID, who may be 
reluctant to attend specialty clinics to access treatment. Some regions in Europe and the USA 
also require documented abstinence from drugs and alcohol prior to accessing HCV therapy87,88. 
Creating barriers for entry to care is a major challenge to elimination, and these restrictions 
have not been supported by evidence. Indeed, there is accumulating evidence, for example, that 
treatment outcomes are equivalent in those with and without ongoing substance use, with high 
sustained viral response rates (94%) documented in individuals with ongoing active injection 
drug use89.   
 
There is some evidence, albeit limited, that the use of case managers and peer outreach 
workers to schedule and accompany individuals to appointments, as well as the use of cash 
incentives, increases rates of attendance to specialist care90,91. There is also some evidence that 
integrating HCV care into drug, alcohol and psychiatric services can increase treatment uptake 
92. Although it seems intuitive that management of HCV for PWID should be integrated into 
existing care models, controlled data showing the benefits of this approach, particularly in the 
interferon-free era, are limited, and data on screening and linkage to HCV care for PWID in low-
income and middle-income countries are scant, despite an increasing burden of disease in many 
countries in this population.  
 
Until recently, the requirement for liver biopsy to assess the extent of liver fibrosis was a major 
barrier for retention in care. Transient elastography (TE) and other non-invasive measures of 
liver fibrosis have now largely replaced liver biopsy, and the immediacy of TE results makes it 
particularly attractive. Use of TE was shown to increase engagement in follow-up care among 
people with recent injection drug use, particularly for those with high fibrosis scores93. In most 
low-income and middle-income countries, where access to both TE and liver biopsy is very 
limited, alternative measures such as APRI and FIB-4 may be useful. These biomarkers have 
excellent negative predictive value for cirrhosis (APRI<1 93% NPV for cirrhosis) and are 
universally available; these test might also be useful in selecting patients who do not need 
follow-up for HCC screening after achieving SVR, as suggested by one US-based study94.  
 
Restrictions on the eligibility of prescribers are not only a barrier to continuity of care, but also 
to implementation of task-sharing approaches. The simplicity, safety and finite duration of DAA-
based HCV treatment allows for a shift away from specialised clinics and toward primary care. 
Relatively straightforward algorithms for diagnosis, pre-treatment work-up and selection of 
optimal therapy have been developed, allowing primary care providers, including nurses, 
physician-assistants and other allied health professionals, to oversee HCV care. Australia, for 
example, now permits a broad range of DAA prescribers—a shift from their initial policy of 
requiring specialists to approve prescriptions from primary care providers—resulting in 
improved HCV management in primary care settings95. High quality evidence is emerging to 
support care outside of specialised services96 and no doubt much more will emerge. Nurse-led 
models have shown improved rates of patient satisfaction with overall care and higher rates of 
treatment completion compared to treatment in a hepatology clinic92,97. Task-sharing is 
particularly attractive to provide care in rural and remote communities as well as to serve 
particular populations, such as PWID. Task-sharing has worked well in LMIC for management of 
patients with HIV and TB and could be adopted for viral hepatitis care in this setting; however 
this strategy is being used in very few countries.  
 
Historically, the largest drop-offs in the HCV cascade of care occur between antibody screening 
and confirmatory HCV RNA testing and then between diagnosis and attendance at first clinic 
appointments98,99.  As such, approaches to minimise these gaps are a priority. Particularly for 
marginalised populations, outreach into the community to test and immediately engage people 
into care (test and treat) has been advocated. Offering patients treatment in familiar settings 
from trusted providers enhances treatment uptake and retention91,100.  This type of approach 
has been particularly important for reaching populations with significant social challenges, such 
as those with on-going mental health and substance use issues or those in unstable housing.  
Delivery of HCV treatment in OST clinics, community health centres and drug and alcohol 
support programs has demonstrated positive outcomes that extend beyond HCV cure rates,100  
including increased diagnosis rates. Modelling data suggest that a ‘bring-a-friend’ strategy of 
care amongst members of drug-using networks will be more effective at reducing prevalence 
and preventing reinfection than strategies targeting treatment randomly 101. Studies formally 
evaluating this approach are ongoing. Numerous outreach programmes have been designed, 
particularly in large urban centres, with initial data supporting the use of peer navigators to 
assist with linkage to and retention in care, provision of care by nurses and primary care 
physicians rather than specialists, and integration of HCV treatment into multidisciplinary care 
to address other health and social issues102,103. Initial results suggest that such models are 
effective, with cure rates comparable to or better than those seen in clinical trials and real-world 
cohorts treated in hepatology and infectious disease clinics96. To reach the very ‘hard-to-reach’, 
more aggressive outreach programmes are being evaluated such as mobile vans equipped to 
screen for HCV, offer portable TE testing, and dispense and monitor therapy. Notably, these 
vans are staffed by trained nurses and peer outreach workers with no involvement of specialist 
physicians. It will be important to formally evaluate outcomes, acceptability and cost-
effectiveness of various outreach programmes to develop best practices that can be broadly 
implemented.   
 
Outreach programmes must take into account cultural-specific considerations that may impact 
how HCV is best managed in particular communities, such as PWID, Aboriginal communities, and 
Native American communities. As such, it is critical to involve community members in the design 
and implementation of screening and treatment strategies. Ensuring simplification of care is a 
key priority if rapid increases in diagnosis are to be achieved. The excellent safety profile of 
approved DAA therapies has reduced the need for on-treatment monitoring. While most 
treatment guidelines still advocate for on-treatment HCV RNA testing to confirm adherence, as 
well as periodic (usually monthly) laboratory testing to confirm safety, there is no evidence that 
such testing and monitoring is necessary to improve treatment outcomes. Studies of simplified 
monitoring strategies are underway (e.g. SMART-C, NCT03117569) and such approaches will 
ultimately need to be tailored to local settings and resources.  
 
Cascade of care and improving care models for HBV [H4] 
 
The natural history of HBV is more complex than for HCV, and differences in the disease course 
between geographical areas mean disease management algorithms are more complicated than 
for HCV infection.  This complexity is a challenge for providing and evaluating continuity of care. 
Unlike HCV or HIV, where the presumption is that all infected individuals should be treated, this 
is not the case for HBV. For example, non-cirrhotic individuals who are HBsAg positive but do 
not have detectable HBV DNA (ie, who are not actively infected) may not require treatment. 
Assessing the proportion of HBV-infected individuals in need of treatment and determining what 
percentage of treatment-eligible individuals with HBV are currently receiving treatment is 
challenging. There is also no consensus about which infected individuals require treatment, and 
the need for treatment may change over time, necessitating multiple follow-up visits104. There is 
a clear need for more studies in different settings to document the optimal continuum of care. 
 
The complexity of many current HBV management guidelines, including those published by 
WHO, can be an obstacle to adopting simplified models of care, such as task sharing105. 
Developing locally relevant and robust algorithms must be a priority to help scale up HBV 
treatment in resource-limited settings.  A recent study from West Africa162 described and 
validated a scoring system (TREAT-B) based on serum HBeAg and ALT levels to identify patients 
who required therapy. As HBV treatment coverage increases with the availability of generic 
versions of the antiviral drugs entecavir and tenofovir, application of such simplified models of 
assessment will be a priority to support practitioners in resource-limited settings to 
appropriately manage patients with HBV.  Similar to the situation with HCV, simplified non-
invasive measures of fibrosis (APRI/FIB-4) may be adequate in most settings to identify patients 
requiring treatment, but their diagnostic performance need to be confirmed in specific 
populations106 
 
In terms of management of individuals with HBV, it is attractive to link HBV care into existing 
models of HIV management. The mainstay of HBV therapy, tenofovir disproxil fumarate (TDF) is 
also used to treat HIV, making many providers familiar with the drug’s profile. In addition, many 
systems to manage HIV have the potential to be specifically tailored to be suitable for resource-
limited settings, which can be easily adapted for follow-up of people with HBV. 
 
Improving diagnostics [H3] 
 
Monitoring requirements for HBV are similar to those already in place for HIV, with stable 
asymptomatic patients generally attending care every 6 months. The introduction of direct-
acting antiviral drugs for HCV, particularly those with pan-genotypic activity, that can be used 
without eligibility criteria based on fibrosis or a measurement of a log drop in viral load to track 
treatment response, now allows for the dramatic simplification of diagnostics to support HCV 
treatment programmes. For the first time, this offers countries a feasible path to implement and 
scale-up programmes. However, large technology and funding gaps exist across both HBV and 
HCV diagnostics, especially in terms of point-of-care technologies. With HIV, the limiting role of 
diagnostics and monitoring tests in scaling up therapy was not well recognised early in the 
strategic response to the disease. Only with the WHO/UNAIDS Treatment 2.0 strategy did 
diagnostics achieve prominence, resulting in increased efforts to roll out HIV viral load testing 
and to implement novel methodologies for point-of-care detection. It is important to note that 
progress in improving access to HIV rapid diagnostics has been underpinned by strict quality 
approval of tests and large donor support; similar efforts are needed for hepatitis. The first 
WHO Guidelines for Hepatitis B and Hepatitis C testing highlight the need for such a response107. 
Elimination of viral hepatitis cannot be achieved without comprehensive access to affordable, 
feasible and quality diagnostics, in order to define the epidemic, focus programmatic resources, 
and allow simplified pathways for diagnosis and care. 
 
Rapid-detection tests and point-of-care diagnostics [H4] 
 
Advances in rapid diagnostic technologies have created new opportunities for enhancing access 
to testing and care, as well as monitoring treatment response, a number of which were recently 
reviewed 108. These alternative sampling methods (use of dried blood spots, oral fluids, self-
testing) and combination of rapid diagnostic tests for simultaneous detection of HIV, HBV and 
HCV infection. More affordable options are also being explored for confirmation of active 
infection (HBV DNA and HCV RNA), such as point-of-care molecular assays, HCV core antigen 
and multi-disease polyvalent molecular platforms that make use of existing centralised 
laboratory-based or decentralised TB and HIV instrumentation. Health system improvements, 
such as integration of laboratory services for procurement and sample transportation and 
enhanced data connectivity, can be used to support quality assurance and supply chain 
management. 
 
Most traditional serological methods for the detection of HBV and HCV are laboratory-based 
and, although rapid diagnostics tests are available (see supplemental tables 1-3), there is 
significant variability in their performance as alternatives to laboratory-based 
immunoassays. Recent systematic reviews of 33 rapid detection tests for HBsAg and of 30 rapid 
detection tests for HCV-specific antibody reported high pooled sensitivity and specificity values  
respectively, but with a lower sensitivity of the HBsAg tests in HIV-positive patients (72%). 109,110 
 
Oral tests for detection of HCV-specific antibodies have slightly lower pooled sensitivity but 
comparable sensitivity compared to blood-based tests, and may be particularly useful in 
contexts where venepuncture may be difficult, such as subsets of PWID. Among the existing 
rapid detection tests for HCV, OraQuick HCV Rapid Antibody Test (OraSure Technologies, 
Bethlehem, Pennsylvania) is the best-performing and the only US-FDA approved rapid detection 
test for HCV. However, given the current pricing of the OraQuick test at roughly USD10 per 
test111, it is unlikely to be widely adopted in resource-limited settings, and more affordable tests 
with comparable performance as the OraQuick and documented accuracy in both in HCV-
monoinfected and HIV-HCV co-infected people, are urgently needed.  
 
One antibody-based rapid detection test for HBV and two for HCV have received WHO 
prequalification. Several CE-mark assays are commercially available but not have not been pre-
qualified170. The WHO Prequalification Programme assesses the performance of in-vitro 
diagnostics using samples from diverse geographic regions and their suitability for use in 
resource-limited settings. More prequalified diagnostics are needed to ensure that test quality 
remains at the centre of procurement processes. However, in many low-income and middle-
income countries procurement tenders are often based solely on price and therefore many 
companies are not incentivised to seek pre-qualifications. Countries should ensure that have a 
competent regulatory body that follows guidance of the International Medical Device Regulators 
Forum (formerly GHTF)112.  
 
The WHO recently launched a model Essential Diagnostics List (EDLs) to satisfy the priority 
health care needs of the population. This should help strengthen quality assurance, human 
resource training and supply chain management. The inclusion of viral hepatitis diagnostics in 
this list will help to galvanise programmes to offer tests and facilitate mechanisms to improve 
affordability.  
 
Detection of virus is important not only for diagnosing active infection, but also for screening in 
blood transfusion services, which is a priority area for scale up. The majority of low-income and 
middle-income countries use serological assays for blood screening, because they are usually 
simpler and more affordable than molecular testing113. However, these tests often suffer from 
high rates of false-positivity, resulting in unnecessary discarding of blood114. As blood safety 
tests are subject to stricter regulatory requirements compared to diagnostic tests, few options 
exist for low-income and middle-income countries, and no options are available for point-of-
care or emergency settings. Rapid detection tests may be used in these situations, although they 
are not designed for blood safety testing and may be less sensitive than enzyme-based 
immunoassays, leading to transfusion of potentially infectious blood113,114. The implementation 
of better quality control and assessment and more feasible product solutions are therefore 
urgently needed63. 
Access to tests that directly detect virus remains essential for both HBV and HCV, particularly as 
test-and-treat strategies are rolled out. For HBV, like HIV, assessment of viral load remains the 
preferred means of monitoring treatment efficacy, and for HCV, increasing availability of 
treatment will result in increasing proportions of individuals with detectable HCV-specific 
antibodies but no detectable virus.  
 
There are few options for HBV DNA testing in resource-limited settings, and there are currently 
no WHO prequalified HBV DNA tests, although a number of polyvalent laboratory-based 
platforms have stringent regulatory authority (SRA)-approved assays. Although laboratory-based 
options exist for HBV DNA testing, sample acquisition and transport can be challenging, costs 
are high, and availability is limited. There are only two near point-of-care test cartridges in 
development for HBV DNA detection in serum of plasma (from Cepheid and Mobio diagnostics).  
 
SRA-approved assays for active HCV infection exist, including several laboratory-based and one 
near patient option (suitable for use in or adjacent to clinical areas) from Cepheid (the CE-
marked HCV Viral Load cartridge and instrument, Cepheid AB) that requires serum or 
plasma.111,115 The Cepheid AB test is also the only WHO prequalified test available, but only two 
studies have been conducted to date in resource-limited settings of India 116  and Cambodia 117. 
Additionally, Cepheid has recently developed a redesigned cartridge to allow the use of whole 
blood from finger pricks with high accuracy, 118 which will help overcome challenges associated 
with venepuncture in certain patient groups and will simplify sample processing and accelerate 
results. Another near-point-of-care assay that has been recently CE-marked is the Genedrive 
HCV ID Kit (Epistem Ltd, UK)119; however, this system requires serum or plasma and an 
interrupted power supply, therefore being most suitable for decentralised testing at the district 
healthcare level119.   
 
Detection of HCV core antigen, may be an alternative strategy to HCV RNA testing120,121 for 
detecting active viral replication, and a one-step HCV diagnostic strategy may be a solution for 
some high prevalence settings. The current guidelines recommend antibody screening followed 
by confirmation of active infection using a test for the virus itself, whether via HCV core antigen 
or RNA testing; however if a cheaper, highly sensitive, point-of-care version of the core antigen 
test could be developed, it could replace the two-step antibody plus viral confirmation 
approach. A one-step core antigen testing strategy would also help to overcome the low 
sensitivity of antibody screening tests in immunosuppressed individuals that lead to false 
negative results. To date, only one highly sensitive core antigen test exists, the Abbott 
ARCHITECT HCV antigen assay, which requires the use of a large, high-throughput, laboratory-
based, multi-analyte analyser and is not widely available in LMICs. At least one point-of-care 
HCV core antigen test is in development.  
 
Where on-site access to nucleic acid tests is not possible and sample transport systems for 
whole blood, plasma or serum are limited, dried blood spots provide an alternative approach 
that is potentially suitable for a wide range of resource-limited settings29,30. Dried blood spots 
are stable for long periods and at high temperatures and can be prepared from capillary whole 
blood, thus obviating the need for phlebotomy. This sampling approach has been successfully 
implemented in Scotland122,123. Systematic reviews and meta-analyses have demonstrated 
acceptable performance and accuracy of dried blood spots for the detection of HBsAg, HBV 
DNA, HCV antibody and HCV RNA120.  
 
Financing diagnostics [H4] 
 
There is limited information available on the extent of HBV and HCV country guidelines, policies 
and extent of implementation on the ground with regard to HBV and HCV diagnostics. This 
information is essential to ensure that relative comparisons can be made between products, 
countries, and public and private sectors, and will also help to identify the cost drivers that are 
most in need of intervention. A similar approach for DAA pricing has been helpful in advocating 
for price reductions124. For the moment, only manufacturer-provided ex-works or free carrier 
pricing exists for virological HCV tests, along with the technical, implementation and 
procurement information111. Even when manufacturers offer bundled pricing (ie, volume-based 
ceiling prices across a range of polyvalent tests rather than vertical pricing alone), most HCV 
tests are significantly more expensive than their HIV counterparts. Bundled pricing is also 
generally limited to virological tests (ie, excluding tuberculosis, for example, where common 
instrumentation could be valuable), and preferential pricing may be restricted to high burden 
and/or low-income countries rather than including all low-income and middle-income countries. 
 
A lack of donor commitment to hepatitis and a reliance on domestic funding have not only 
delayed the scale-up of hepatitis programmes but have also prevented the development of 
market shaping strategies, such as pooled procurement and increased competition. 
Manufacturers perceive the developing world market as small and fragmented, and lack a 
strong business incentive to invest in hepatitis diagnostics that are better adapted to resource-
limited settings. Available funding is generally limited to diagnostics and treatment for HCV-HIV 
co-infection, and HBV is omitted altogether. Additionally, more detailed policy information on 
out-of-pocket expenses to expose policies and practices that limit access would be useful, as 
diagnostic tests may not be free under public hepatitis programmes. Countries can take 
advantage of the infrastructure already put in place for HIV, especially where manufacturers 
offer bundled pricing across their tests for polyvalent platforms18.  
 
  
Panel 2: Priority steps for countries scaling up testing and diagnosis  
 
Governments and implementing partners:  
 Implementation of in-country hepatitis programmes consistent with WHO 
guidelines (leveraging existing infrastructure from other programmes, such as HIV). 
 Scale-up of patient-centric hepatitis programmes to meet the needs of all those 
affected, including high-risk groups, without necessitating unaffordable, out-of-
pocket expenses that prevent linkage or access to treatment.  
 Access to a competent regulatory body to assess the quality of diagnostics 
 Access to transparent and disaggregated pricing on the full and total costs of 
diagnostics. Price decreases should be facilitated through increased volumes, 
competition, bundled pricing and pooled procurement. 
Ministries of Health: 
 Use of pan-genotypic, DAAs for HCV treatment to enable diagnostic and monitoring 
simplification for increased programmatic feasibility and access to care.  
 Ensure integration of vertical disease programmes and opportunistic cross-disease 
screening, even in vertical disease programmes. 
 Secure access to appropriate diagnostic tests  
 Consider renewing serosurveys if previously carried out with older, less specific 
tests 
 Define priority groups at risk of transmission and patients with severe liver disease.  
 Develop local capacity, evidence and guidance to inform scale up of services and 
simplified protocols suitable for task sharing 
 Engage healthcare workers, civil society and governments by raising awareness and 
education and reduce discrimination.  
 Ensure collection of data on progress towards targets to monitor impact and inform 
the need for changes to testing strategies. 
Diagnostic manufacturers: 
 More comprehensive, manufacturer-led testing of specimen and product stability 
to better understand the limits of transport and storage conditions, including 
alternative sample types, such as DBS. This will help to ensure feasibility and that 
products aren’t used off-label or under research use only. 
 Validation and filing for regulatory approval, by manufacturers, of DBS for serology 
and virology. 
 Manufacturer-led dual claim for virological tests for diagnosis and monitoring of 
cure. 
 Together with funders, additional investment into development of point-of-care 
tests adapted to RLS, including for serology, virology, blood safety and staging. 
International organisations, governments, implementing partners and other stakeholders:  
 The involvement of civil society as a powerful advocacy tool and important voice in 
designing and ensuring patient-centric approaches and access to care.  
  
Access to Medicines for viral hepatitis [H2] 
 
There are different challenges to ensuring widespread access to HBV and HCV treatment. 
Access, to HCV treatment has been a major focus of attention since the marketing of sofosbuvir 
and will be discussed further below , but it is also a crucial time to look at improving access to 
HBV treatment. Two key long-term HBV treatments are recommended in international 
guidelines, tenofovir disproxil fumarate (TDF) and entecavir, which are sufficient for the 
management of most patients. As of 2018, both drugs are off-patent in most major markets 
(excepting Russia and China125). The cost of TDF and entecavir is not a barrier to access in most 
developed economies, but in some markets the potential efficiencies of generic competition are 
yet to be realised. For example, in 2015, generic entecavir retailed in the US for close to the 
same price as the branded drug in Europe (US $6000/year), despite the potential for it be sold 
for under 50 USD /year126.  
 
TDF is now widely available in low-income countries, following its licensing to the Medicines 
Patent Pool in 2006 and voluntary licensing schemes from Gilead,. The key role of TDF in HIV 
combination therapies has meant active competition amongst generics manufacturers, with the 
drug now widely available for under US$50 a year. Despite great progress in HBV drug pricing, 
only an estimated 1.7 million of those infected are on treatment125. In many low-income 
countries there remains a key paradox: funding is often only available for those with HIV co-
infection, not those with HBV infection alone, and prices may be different for each indication127.  
 
Affordability of HCV treatment as a key barrier to elimination has been well documented in both 
the richest and poorest health economies. Both high prices and large numbers of patients in 
need of immediate treatment have created a daunting budgetary challenge to health systems. 
Recent treatment coverage estimates for HCV suggest that few countries are on target to 
achieve elimination of HCV as a public health problem by 2030128 . Of the 71 million people 
globally who are chronically infected, only 1.1 and 1.76 million initiated treatment in 2015 and 
2016, respectively; 86% of treated patients are on DAA-based therapies 125,129. The lack of access 
to affordable treatments is one of the key reasons why many HCV-infected patients are 
undiagnosed, as widespread screening and testing needs to be linked to, and justified by, 
treatment access.  
 
Intellectual property remains a major factor limiting the availability of generic DAAs. Gilead, 
BMS, Merck, and AbbVie have filed several types of patents on each DAA, with patent 
protection status varying by country130. The voluntary license agreements signed by some 
originator companies have enabled generic producers to manufacture and sell versions of 
sofosbuvir, ledipasvir, velpatasvir (Gilead)131, and daclatasvir (BMS-MPP)132 to countries listed in 
the licensed territory.  Consequently, countries included in these agreements should be able to 
procure generic DAAs from multiple licensees at generally affordable prices due to generic 
competition. The “access” prices for countries in the Gilead license territory who procure from 
the originator are approximately 250 USD per bottle of sofosbuvir, and 300 USD per bottle of 
sofosbuvir/ledipasvir or sofosbuvir/velpatasvir133. Where multiple generic sources have 
registered and made their DAAs available, prices can be much lower. The minimum cost of 
production of DAAs, a guide to target generic prices, can be estimated based on the cost of the 
active pharmaceutical ingredients along with the average costs of the manufacturing process for 
tablet formulations, and the profit margin for the generic supplier. The basic minimum cost of a 
12-week course of sofosbuvir and daclatasvir could be as little as approximately 48-81 USD per 
person, including an estimated profit range of 10-50%134.  
 
Some countries have benefitted from a significant reduction in the prices, with resulting 
improvements in access, while others have not yet been so successful. The most significant price 
decreases were seen in India, Pakistan, and Egypt, countries included in voluntary licenses that 
have dynamic generic industries, where 3 months of sofosbuvir plus daclatasvir could be 
procured in local markets at US$423, $240, and $95 respectively in 2017129. In June 2018, the 
Ukrainian Ministry of Health, supported by United Nations Development Programme, 
completed a tender whereby they secured a price of US$20 per bottle of generic sofosbuvir, 
quality assured by WHOPQ, and US$6 per bottle of generic daclatasvir. 
 
Outside of the Gilead and BMS-MPP license territories, countries with a strong negotiating 
capacity and relatively high procurement volumes that allow savings based on economies of 
scale have achieved DAA price reductions with originator companies and have set up ambitious 
HCV elimination targets, as is the case for Australia135. More generally, in countries where DAA 
patents have been granted, competition between branded products has started to bring prices 
down. The 2017 US FDA and EMA approval of Abbvie’s pan-genotypic eight-week 
glecaprevir/pibrentasvir treatment is expected to influence the price of sofosbuvir-containing 
combinations, most notably in countries with a political commitment to universal access to HCV 
treatment.  
 
Price reductions have been less marked to date in upper-middle income countries, which are 
excluded from voluntary licenses. In Brazil, where the Ministry of Health proposes extending 
treatment to all patients with HCV, negotiation with originator companies has resulted in more 
modest price reductions (e.g., 43% vs. 93% in Brazil vs. Egypt for sofosbuvir plus daclatasvir 
between 2015 and 2017)136. The modest nature of the price reduction has widespread 
implications given that Brazil is considered to be a benchmark for the establishment of DAA 
prices in Latin America.  Patent applications on sofosbuvir are still pending examination at the 
Brazilian patent office; however, most applications have received a technical opinion favouring 
rejection; recently a generic sofosbuvir was approved by the Brazilian Health Regulatory Agency 
(ANVISA)137.  
 
In Malaysia, another upper-middle-income country, efforts by the Ministry of Health to 
negotiate a voluntary license and an affordable price for sofosbuvir were unsuccessful. The 
Cabinet issued a government-use license138 to gain access to generic sofosbuvir at a 97% price 
reduction and initiate treatment scale-up129. This resulted in the addition of Malaysia and 3 
other middle-income countries (Thailand, Belarus, and Ukraine) to Gilead’s license territory.   
  
The continuous pressure of over-priced medicines on public health budgets in high-income 
countries has led some of these countries to consider making use of TRIPS agreement 
flexibilities. For example, the Italian Medicines Agency has refused to pay more than US$4,000 
per treatment, and threatened to issue a compulsory license to allow local production if they 
were not able to negotiate a better price with Gilead139. Chile has also taken the first step 
towards issuing a compulsory license to allow importation of less expensive generic drugs140. 
 
Although Abbvie’s pangenotypic HCV combination, glecaprevir/pibrentasvir was approved in 
March 2017, by mid-2018 there was no information available on plans to allow for access 
outside of high-income countries. Ensuring access to glecaprevir/pibrentasvir in low-income and 
middle-income countries might help to scale up therapy given the shorter 8-week duration in 
first-line treatment, but perhaps more importantly, might play a role for re-treatment of 
patients who have failed treatment with other DAA regimens. Currently, the only licensed 
retreatment option for patients failing sofosbuvir-based treatment is the combination of 
sofosbuvir/velpatasvir/voxilaprevir. While this triple combination is included in Gilead’s 
voluntary license, generic companies have not yet started to develop this combination, leaving 
countries who can procure via Gilead’s “access program” to pay US$600 per bottle.  
 
The Drugs for Neglected Diseases initiative, (DNDi) partners with access-oriented 
pharmaceutical companies, middle-income countries, and other treatment providers and 
organisations to provide affordable tools to meet public health needs. As part of an ongoing 
program of development, interim results of a phase II/III clinical trial of sofosbuvir plus the new 
NS5A inhibitor ravidasvir carried out in Malaysia and Thailand showed good efficacy (97% 
SVR12)141. This combination may offer an affordable alternative  for countries, such as Argentina 
and Brazil, that are excluded from the originators’ licenses and where patent applications on 
sofosbuvir are still pending examination or are under legal challenge142. These countries should 
carefully analyse whether these patent applications deserve to be granted according to their 
own patent law and the flexibilities of the WTO TRIPS agreement. Countries that have granted 
patents on DAAs and remain confronted with expensive prices could issue a compulsory license 
on sofosbuvir, following the lead of Malaysia, in order to access the more affordable 
sofosbuvir/ravidasvir regimen. 
 
Registration is an important consideration in access to medicines, as both originator and generic 
companies have regulatory strategies to prioritise countries where they will file their products 
and, for some countries, registration is a requirement to take part in national tenders. The time 
to register a product varies by country, taking as long as several years in some. The WHO pre-
qualification program evaluates the quality of generic medicines for HCV, HIV, TB, and malaria, 
and includes a collaborative registration process whereby approved medicines can be registered 
in less than 90 days in participating countries, reducing the workload involved in drug 
registration for the national drug regulatory authorities and facilitating access to quality assured 
generic sources of DAAs. As of June 2018, three generic formulations of sofosbuvir have been 
prequalified by the WHO (Mylan, Hetero, and Cipla)143. Two additional versions of sofosbuvir 
(Pharco and Strides) and one for daclatasvir (Hetero) are quality assured via the Global Fund 
Expert Review Panel’s risk-benefit analysis process144; additional dossiers for generic DAAs have 
been submitted for WHO-PQ quality assessment. Generic DAAs are not assessed by the U.S. FDA 
(as is done for generic antiretroviral drugs) as PEPFAR has yet to fund treatment for HCV or 
finance quality assessment via the US FDA for generics. With the exception of voxilaprevir, 
glecaprevir, and pibrentasvir, all approved DAAs (including tenofovir and entecavir) are included 
in the 20th WHO Essential Medicines List145. 
 
Both low-income countries and middle-income countries remain underserved in terms of access 
to HBV and HCV medicines. A substantial number of upper-middle-income countries—often 
referred to as the squeezed middle—that have a high prevalence of HBV and HCV but remain 
excluded from voluntary licenses and are faced with expensive prices from originator 
companies. All originator companies with treatments included in the WHO HCV guidelines 
should have access policies that not only allow generic manufacture of the drugs for low-income 
settings, but also ensure equitable access across all middle-income settings. Even in countries 
included in the voluntary licenses, where intellectual property is not seen as a barrier, the major 
issue of financing both HCV and HBV programmes lies ahead.  
 
Innovative Financing for Viral Hepatitis [H2]  
 
Achievement of elimination will depend less on technical capabilities and more on leadership, 
political will and financial considerations. Even when there is strong leadership and political will, 
availability of finances, the application of funds and health system capabilities will determine 
the magnitude and the speed of response. 
 
A relatively modest amount of the new funding for the global response to viral hepatitis will be 
channelled to global development and health agencies to be used for global R&D, surveillance, 
harmonising norms and standards (eg, WHO vaccination schedules for HBV and treatment 
guidelines for HCV), global data and information for shared learning, and generation of 
comparative analyses and evidence146. By contrast, domestic sources currently accountfor most 
of the funding for developing a country-level response to viral hepatitis. These include both 
private sources (eg, private insurance and out-of-pocket payments) and public financing (ie, 
government budget allocated to health). In many of the countries most heavily burdened with 
infection, a majority of health spending is out-of-pocket (see Table 1 ) 
 
At the country level, public financing for health (as for any sector) is determined by the fiscal 
space available to the government,147 which depends on the sources of finance available from 
improved economic growth creating favourable macroeconomic conditions: generation of 
revenues from new taxation or strengthening of tax administration; borrowing from domestic 
and international sources; reprioritisation of health within the existing government budget; 
more effective and efficient allocation of available health resources; and innovative domestic 
and international financing.148 149  
 
With regard to economic growth, all 20 of the countries most affected by viral hepatitis are 
projected to achieve economic growth in the next 5 years according to the International 
Monetary Fund (IMF) . However, while improvements in economic circumstances typically help 
countries to gradually increase domestic financing for health in line with real growth in the GDP, 
these increases do not tend to be rapid or large. Increases in general taxation, from income tax 
or value added tax, are not politically popular. Improvements in collection of taxes takes time 
and when these revenues are realised, they are rarely earmarked for health.  Borrowing from 
domestic or international sources for funding health budgets is unlikely, as the expenditures 
funded by borrowing should lead to improvements in economic growth and help generate 
revenues to service the debt. Reprioritisation of government budgets to allocate a greater 
proportion to health is potentially attractive but requires political leadership and consensus to 
redirect funds from other sectors. Perhaps more promising is more effective and efficient 
allocation of health resources, which could potentially release funds to be reinvested. Indeed, 
WHO estimates that around 20-40% of all health spending is wasted.150 However, even if 
feasible, realising these efficiency gains and reallocating them to viral hepatitis would take time. 
 
The most potentially fruitful source of new and additional funding for health, and in particular to 
catalyse a response to viral hepatitis, is innovative domestic and international financing, which 
was identified as a promising source of new and additional financing for global health to help 
meet the MDGs at The International Conference on Financing for Development held in 
Monterrey, Mexico, in 2002151,152. Many countries have successfully used domestic and 
international innovative financing to mobilise new and additional resources for health. 
Domestically, for example, countries such as Egypt, the Philippines, and Thailand have used 
targeted taxes on tobacco to provide earmarked funding for the health sector.153 Financing from 
international innovative financing has been more promising than domestic sources to catalyse 
and accelerate response to epidemics such as HIV, tuberculosis and malaria. As such, a brief 
analysis of the international innovative financing landscape—in particular innovative financing 
mechanisms154 and innovative financing instruments155—is instructive to learn lessons and to 
explore how such mechanisms and instruments could be used for viral hepatitis. 
 
To date three innovative financing mechanisms154 have reached global scale, namely the Global 
Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund, established in 2002)156, GAVI 
(established in 2000)157 and UNITAID (established in 2006)158. These innovative financing 
mechanisms link different elements of the financing value chain to mobilise funding from 
multiple sources (such as governments, private foundations, and the private sector), pool 
finances, channel and allocate funds to health programmes through implementing organisations 
and governments in low-income and middle-income countries. By 2017, the Global Fund had 
disbursed US$ 33.8 billion159 for HIV/AIDS, tuberculosis, malaria and health systems; GAVI had 
disbursed US$11.2 billion160 for vaccines; and UNITAID had invested more than US$2 billion161 in 
medicines, diagnostics and health products for HIV/AIDS, drug resistant tuberculosis, malaria, 
and HCV. 
 
These financing mechanisms have innovated to improve each step of the finance value chain 
and enhance linkages between and integration among steps, to create additional value in 
financing. This has allowed for additional funding to be rapidly channelled to health 
programmes and has created incentives to improve implementation and performance of these 
programmes to achieve better health outcomes at a large scale154. While the Global Fund and 
GAVI mobilised and disbursed large amounts of new funding, UNITAID was able to strategically 
leverage its funds by focusing on improved market dynamics for new medicines, diagnostic and 
health products to substantially lower prices and to improve access. 
 
In addition to innovative financing mechanisms, several innovative financing instruments have 
been developed,155 ten of which have reached scale to mobilise around US$8·9 billion in 2002–
15. The funds generated by innovative instruments were channelled mostly through GAVI and 
the Global Fund, and used for programmes for new and underused vaccines, HIV/AIDS, malaria, 
tuberculosis, and maternal and child health.235 These instruments have different characteristics 
in relation to the nature of funding, amount of funding raised, the mechanism used to raise 
funds, the flexibility by which the funds raised could be used, and the timing of application of 
funds relative to when the funds were mobilised. 
 
Global Health Bonds 
 
The International Finance Facility for Immunisation, IFFIM162, uses donor funds or future pledges 
as security to issue bonds in capital markets, thereby monetizing the pledges. The proceeds 
from the bond are then channelled to GAVI, the Vaccine Alliance, and made available to 
countries to invest in immunizations programmes. The monetization of future pledges through 
bond issuance enables funding to be made available immediately for immunization 
programmes, to ‘front-load’ funding and to accelerate uptake of new and existing vaccines. 
 
Debt conversion Instruments 
 
Instruments such as Debt2Health163, the World Bank Investment Partnership for Polio 
International Development Assistance Buy-Back Program (IDA Buy-Back)164, the Japan 
International Cooperation Agency Overseas Development Assistance Loan Conversion Program 
for Polio (ODA Loan Conversion), are debt conversion instruments, which convert credits/loans 
to grants, often with conditions of meeting a health or social target such as achieving 
immunization coverage.  
 
With Debt2Health, another debt conversion instrument, the debt swap agreement is executed 
between a creditor and a debtor country (the beneficiary), whereby the creditor forgoes a 
portion of a debt on the condition that the debtor country invests an agreed counterpart 
amount on national health programs. The investment is made by contribution to the Global 
Fund according to a schedule established as a part of a debt swap agreement.   
 
Buy-downs, such as IDA Buy-Back or ODA Loan Conversion, allow a third party to buy-down all 
or a part of a loan, either by softening the loan terms or by paying down interest and/or 
principal amount. The buy-down releases the loan recipient (the debtor country) from all or part 
of future obligations for repayment of principal or interest, thereby allowing those resources to 
be earmarked for health or social programs. The strength in buy-down arrangements stems 
from the third party mandating that the borrower invest the repayment resources in health and 
social programmes, often with terms are tied to performance objectives, such as reaching 
immunization or treatment coverage targets.  
 
Market Commitment Instruments  
 
The Affordable Medicines Facility for Malaria (AMFm)165,166 has been used to make available 
affordable effective malaria treatments (artemisinin based combination treatments – ACTs) 
through the public and private sector institutions and non-governmental organisations (NGOs) 
and to displace less effective treatments from the market. The funds for AMFm, which came 
from donor countries, were pooled at an innovative financing mechanism (in this case the 
Global Fund), were then used to negotiate with manufacturers of ACTs, which met quality 
criteria, to achieve a price reduction in return for predictable and increased volumes of 
medicines supplied by the manufacturers. The price of ACTs are further reduced through a 
subsidy from the host financing mechanism to the public or private sector buyer, via a co-
payment at the top of the global supply chain.  
 
The Advanced Market Commitments Pilot for Pneumococcal Disease167, used donor funding or 
pledges to establish legally binding long-term purchase commitments for new vaccines. The 
availability of long-term commitments enabled encouraged vaccine manufacturers to invest in 
new vaccines with pre-negotiated prices subsidized by donors and recipient countries and 
predictable volumes.  
Social and Development Impact Bonds 
An alternative and promising funding instrument, which is new to health, is a Social Impact 
Bond, which is constructed by a government agency that wishes to achieve a desired social or 
health outcome.168 An external organization or contractor is then engaged to achieve the 
outcome. A third-party investor provides upfront working capital as an at-risk investment. With 
working capital, the external organization then sets up programmes or interventions to achieve 
this outcome, either through direct service provision or through intermediary service providers. 
If the desired social outcome is achieved, the government releases payment to the external 
organization, based on terms specified in an upfront contract.  Levels of payment are typically 
based on the amount of savings that accrue to the government due to the success of the 
programme.  If the outcome is not met, the government disburses no payment. The external 
organization then repays its investors their principal plus a return on the investment. 
 
Development impact bonds are a variation on the social impact bonds, with the main distinction 
that the payment to third-party implementers upon successful achievement of pre-specified 
outcomes comes from an external funder (e.g. a development agency or a charitable 
foundation), rather than a government169. Social and development bonds enable private 
investors to invest in social problems by taking a risk but with an opportunity to generate a 
return on investment with successful outcomes that also generate savings for the government 
or the development agency.  
 
Global solidarity taxes and levies 
 
Financial transaction taxes, especially those that can help reduce excessive speculation in 
financial markets, is another possible and potentially very large source of new funding for health 
in general and viral hepatitis in particular. Several countries, such as South Korea, Hong Kong, 
India, Brazil, Taiwan, South Africa and Switzerland have already introduced financial transaction 
tax to generate general tax revenues. 
 
A further potential innovative financing instrument, modeled on the successful Airline Solidarity 
Levy10, is a micro tax on data transmission, applied to mobile phone usage.  With the airline 
solidarity levy, participating countries implement a tax (levy) on airline tickets for flights 
originating from local destinations. Each country determines the amount, nature and collection 
mechanism of the levy. Resulting proceeds are donated to UNITAID either as a companion to 
budgetary contributions or as an independent contribution.10  
 
Innovative financing holds much promise to provide catalytic funding to augment funding from 
domestic sources in order to rapidly scale up treatment access to diagnostics and medicines for 
viral hepatitis. There is enough evidence on the success of innovative financing instruments in 
mobilizing funds and innovative financing mechanism to channel them to countries to provide a 
rapid access to novel diagnostics and treatments. There is an opportunity to utilise a 
combination of innovative financing instruments, by replicating those with a record of success, 
to mobilise and ‘frontload’ funding to augment domestic funds in order to rapidly invest in 
diagnosis and treatment of viral hepatitis. Frontloading of funds to rapidly expand access to 
treatment will enable, beyond the individual health benefits and cure, realization of beneficial 
effects of ‘treatment as prevention’ to interrupt then halt transmission to achieve elimination. 
Several steps are needed to make this a reality, however.  
 
As a first step, with the support of donors, political leaders, civil society and affected countries, 
consideration should be given to launching a global coalition of stakeholders to create an 
innovative financing initiative for viral hepatitis. The involvement of civil society is critical in 
mobilising global and national support and to create a movement to secure a commitment to 
viral hepatitis elimination. Civil society has the legitimacy to act as independent champions of 
patients’ rights to achieve equity and hold governments to account. Visible leadership from 
senior politicians is also critical to generate country and global level responses.  
 
The second step should involve the development of an investment case for viral hepatitis, to 
demonstrate the feasibility of elimination and quantify health and economic benefits of 
potential investments, to demonstrate the substantial health, social and economic returns to 
investment. For example, a recent analysis on HCV in Egypt has estimated the economic impact 
of the HCV epidemic on Egypt to show that as of 2015, HCV epidemic reduced GDP by 0.3% and 
by $1 billion each year, and additionally led to a drop in living standards equal to 1.5% of GDP 
and GDP per capita and $5 billion each year. The study estimated that the spending on demand-
driven treatment would be re-financed by savings in costs of within 6 years, and carried a 
financial rate of return of 24 percent, even before taking into account the values of any health 
gains. The study showed that elimination was cost effective, and treatment and screening 
policies would achieve considerable health gains largely cost-free and reduced mortality results 
in a gain in living standards equivalent to 0.6 to 0.8 percent of GDP170. 
 
The third step is to identify and secure commitment from an innovative financing mechanism to 
pool, channel, allocate and monitor effects of financing. The evidence suggests that establishing 
a new financing mechanism is challenging, with only three reaching global scale to date.3 
Further, in addition to inherent risk of failure, establishment of a new funding mechanism in an 
already crowded global architecture would not be timely nor is it likely to be welcomed by the 
donor community. UNITAID, which is already a funder of HCV programmes, and has 
collaborated with GAVI, a funder of HBV vaccine programs worldwide, to introduce new 
vaccines, appears to be the most promising innovative financing mechanism for viral hepatitis 
elimination. As an innovative and lean institution, UNITAID has had demonstrable success in 
shaping market dynamics to achieve substantial reductions in prices of innovative diagnostics 
and medicines and to expand access. UNITAID would be well positioned to house a new 
innovative financing facility for viral hepatitis elimination, which could be funded from multiple 
sources, such as from donors, philanthropic agencies, private sector and innovative financing 
instruments (such as solidarity levies). In addition, UNITAID has successfully established and 
hosts the Medicines Patent Pool, which negotiates with pharmaceutical companies that hold 
patents to obtain licences for the production and distribution of generic versions of patented 
medicines for hepatitis C in low-income and middle-income countries.   
 
As a fourth step, several innovative financing instruments with successful track records could be 
replicated to mobilise new and additional funding for the innovative financing facility for viral 
hepatitis elimination. Four innovative financing instruments could be created or used to this 
end. First is a global health bond, similar to The International Finance Facility for Immunisation , 
which can be used to mobilise funds and pledges from donors and countries to create a bond, 
which then enables frontloading of investments for rapid scale up of treatment. Second, a 
market commitment instrument that combines the experiences of Advance Market 
Commitment and The Affordable Medicines Facility for Malaria, could be used to generate 
agreements between existing and potentially new producers of diagnostics and medicines for 
viral hepatitis to commit to future volumes of diagnostics and advance market in return for 
lower prices. Third, a debt conversion instrument akin to Debt2Health or Buy-Downs for Polio 
Elimination, could be used by creditor nations to encourage affected debtor countries to invest 
in viral hepatitis elimination and achieve elimination targets, in return for debt forgiveness, or 
buy-down of debt or interest payments. Finally, a social or development impact bond, which 
brings together donors, affected countries, private investors and innovative organizations, could 
produce impactful results to eliminate viral hepatitis. Depending on the setting and the need, 
each of these instruments could be utilized. For example, an advance market commitment 
instrument could be used to ‘frontload’ screening, diagnosis and treatment to accelerate 
elimination in countries with high prevalence of HBV and HCV, or a social impact bond could be 
used to expand a programme in countries where programmes exist but are not well-established 
or impactful. Debt conversion instruments would be useful in countries where domestic 
financing is low and where programmes do not exist to stimulate investment and programme 
development  
 
The presence of highly effective interventions to prevent and treat viral hepatitis and to 
interrupt and halt transmission, offers the promise of rapid elimination to prevent unnecessary 
deaths, as well as adverse social and economic impact. There is an urgent need for global 
collective action to accelerate expansion of worldwide access to prevention and treatment of 
viral hepatitis treatment. Innovative financing, with its untapped potential, holds the promise of 
being the catalyst for elimination of viral hepatitis.  
 
  
 
 
 
Panel 3: Key recommendations – access to medicines and financing 
 
Access to Medicines 
 
 Access to HBV treatment should remain a priority at a time when there is greater focus 
on HCV treatment 
 
 Intellectual Property Rights remain a barrier to accessing treatment, particularly in 
upper-middle income countries. Countries needs to consider compulsory licensing if 
affordable prices cannot be achieved 
 
 All originator companies need to ensure there is an access policy for low/low-middle 
income settings for drugs approved on WHO Essential Medicines List 
 
 Countries should take advantage of the collaborative registration process available 
through WHO pre-qualification  
 
Financing 
 
 Consideration should be given to launching a coalition of stakeholders to create 
innovative financing for viral hepatitis elimination , particularly focussed on high 
burden/ low income countries 
 
 Innovative financing tools developed for HIV, TB, malaria and vaccination programmes 
can be adapted for viral hepatitis e.g. advanced marketing commitments, global health 
bonds and debt conversion instruments 
 
 Greater emphasis needs to be placed on developing investment cases for viral hepatitis, 
demonstrating the returns on investment in elimination  
  Table 1 20 countries GDP and health spend per capita, including out-of-pocket 
expenditure for 20 countries with greatest burden of viral hepatitis 
 
 
  
5.1 Viral hepatitis in Asia [H2] 
 
Asia experiences a greater challenge from HBV and HCV infections than any other region of the 
world,9 with half of the 20 most heavily burdened countries residing in this region. The region 
accounts for 74% of deaths from liver cancer globally, mainly attributable to HBV and HCV171. 
Countries in Asia with a high burden of viral hepatitis span the economic spectrum from high 
income (Japan, South Korea), to upper-middle income (China, Thailand), lower middle income 
(Bangladesh, Indonesia, India, Pakistan, Myanmar, Philippines, Vietnam) and low-income 
countries (Nepal, North Korea). There is a negative correlation between GNI and prevalence of 
both HBV and HCV in the region, with a greater burden in lower income countries172  
 
Deaths from viral hepatitis-related cirrhosis and liver cancer increased between 1990 and 2013 
in all 13 Asian countries and territories included in an analysis of GBD data by the Coalition to 
Eradicate Viral Hepatitis in Asia Pacific (CEVHAP)270. Deaths from HBV-associated liver cancer 
increased from 1990 to 2013 in many countries/regions, most dramatically so in Myanmar, 
Taiwan, Vietnam and Thailand, whereas deaths due to HBV-related cirrhosis declined in 
Bangladesh, China mainland and Vietnam. Whether the decline in cirrhosis in these countries is 
real or a consequence of challenges in recording cirrhosis cases is unclear, particularly in view of 
the concurrent rise in cancer deaths. China dominates the regional burden of viral hepatitis and 
is particularly challenged by HBV (figure 5.1a), with more than around 80 million people 
estimated to be chronically infected12.  
 
Success stories and ongoing challenges [H3] 
 
Major success stories in the region relate to implementation of highly successful programs of 
hepatitis B vaccination, inclusion of hepatitis B treatments in social health insurance programs 
and the wide spread availability effective generic DAAs for treatment of HBV and HCV infection. 
However significant challenges remain, including ongoing mother to child transmission of HBV, 
unsafe injection practises and still-limited access to DAAs despite availability of generics. 
 
Several high-income countries and territories within Asia—including Japan, South Korea and 
Hong Kong—have demonstrated what can be achieved by scaling up HBV vaccination. All three 
countries or territories have long-standing vaccination programs, but they have differed in their 
success to date. Vaccination was introduced in Hong Kong in 1983, with universal 
implementation in 1988173. As a result, a marked decrease in the prevalence of HBV in Hong 
Kong was reported in pregnant women born after 1984 compared to those born before 1984, 
with the former up to 68% less likely to be infected by HBV174. Vaccination of healthcare workers 
in Hong Kong was also prioritised in 1983 and is now a key method of maintaining immunity in 
medical workplaces175. Japan similarly prioritises vaccination of healthcare workers, but only 
recommends vaccination of newborns of HBV-infected mothers176. Neonates in Japan are also 
treated with HBIG. Of all high burden countries, Japan has shown the greatest relative decline in 
mortality from viral hepatitis since the GBD programme began in 1990, falling from a ranking 8th 
to 16th  in terms of mortality from hepatitis. Among lower income countries, Bangladesh was 
one of the first to introduce HBV vaccination in 2003 and as a result, HBV prevalence in 
Bangladesh had declined from 8% in 1984 to 5.4% in 2007177. 
 
 
China has met and exceeded the WPRO target for HBV vaccination and reduction of HBsAg 
prevalence  among those under 5 years old.  In mainland China, universal HBV vaccination in 
newborns started in 1992 and the vaccine has been free of charge since 2002 and vaccination 
service for newborns has also been free since 2005178. High coverage of infant vaccination in 
China, resulting in part from the 2002 Expanded Programme on Immunisation, has reduced 
HBsAg prevalence  from 9.8% in 1992 to 7.2% in 2006 among individuals aged 1-59 years, from 
10.7% in 1992 to <1 % in 2014 among those aged less than 15 years, and from 9.7% in 1992 to 
an estimated  0.32% in 2014 in those aged less than 5 years179. The enormous effort and great 
success in prevention and control of HBV by universal vaccination in China have been highly 
praised by WHO and awarded by WPRO. 
 
Timely birth dose of HBV vaccine is a key to preventing mother-to-child transmission of HBV in  
China180, where the prevalence of HBsAg in women aged 20-49 years in rural China was around 
6% (approximately a third of them were also positive for HBeAg) in 2014.181 To increase the 
timely provision of birth-dose vaccine in China, institutional delivery of babies is encouraged and 
is subsidised for women who live in remote areas. Since 2010, the government has also offered 
free prenatal testing for HBV, HIV, and syphilis, as well as free HBIG for babies born to mothers 
who are HBsAg-positive. Clinical studies have shown that antiviral therapy with TDF, telbivudine 
or lamivudine in mid-late pregnancy virtually eliminates  mother-to-child transmission of HBV in 
mothers with high viral load182. In addition, the Hepatitis B Shield Project, initiated in 2015, aims 
to reduce or eliminate mother-to-child transmission of HBV via standardised management 
including timely administration of birth dose of HBV vaccine and HBIG for newborns of mothers 
with HBsAg positivity, and antiviral therapy during the third trimester for mothers with high viral 
load. By March 2017, 106 project hospitals have been recruited into the project, more than 
2,000 doctors have been trained and 4,502 pregnant women infected with HBV have been 
treated under the scheme. 
 
In terms of access to medicine, basic social health insurance programmes are now estimated to 
cover 95% of the population of mainland China, and antiviral drugs for HBV—including 
conventional interferons, pegylated interferons, entecavir, lamivudine, adefovir and 
telbivudine—have been included in the national list of reimbursement for the insured since 
2010 178. Due to the advocacy of all stakeholders, the price of TDF for treating HBV has been 
dramatically reduced in China mainland through government negotiation, and the price of 
entacavir has been reduced by generic manufacturing. As a result, the proportion of individuals 
with access to the recommended entecavir or TDF183 has steadily increased in the past years 
(from less than 20% in 2003 to more than 70% in 2016). To promote standardisation of clinical 
management of chronic HBV, a 2-year continuing medical education program has been  offered 
to more than 9000 local doctors who work at hospitals in 60 small or intermediated size cities 
which are home to most of the population who are chronically infected with HBV in mainland 
China (Jia, personal communication).  
 
To reduce HBV transmission associated with blood transfusion or blood product use, the 
Chinese Ministry of Health mandated screening of blood donors for HBsAg in the early 1980s 
and for HCV-specific antibodies since 1993. In 1998 monetary compensation for blood donation 
was outlawed and donated blood has been tested for HBV DNA and HCV RNA since 2015. As a 
result, infection with HBV or HCV caused by unsafe blood transfusion is now very rare. These 
policies have also contributed in a dramatic decline in the prevalence of anti-HCV antibodies 
from 3.2% in 1992 to 0.43% in 2006178.   
 
Unsafe medical injection remains a major challenge in the region. In 2015, WHO launched new 
injection safety guidelines184, which included a recommendation that by 2020 all Member States 
should switch to exclusive use of safety engineered injection devices. Motivated by this 
recommendation, a study based in a large district in rural Pakistan showed that a community-
based intervention designed to improve knowledge and practice of safe medical injections could 
substantially improve both awareness of the association between unsafe injections and viral 
hepatitis and clinical practice (eg, an increase in reported use of new needles from 15% to 
29between 2011 and 2012)185. In India, high-level political engagement has led to initiatives 
within the State of Punjab, including establishment of 40 model injection safety centres at 
district-level health facilities and medical and nursing institutes throughout the State, which also 
serve as a training resource for health workers on injection safety and reuse-prevention 
measures. 
 
Although access to treatment with DAAs is still limited within the region (see table 5.1), India 
and Bangladesh have become global powerhouses for the manufacturing of generic antiviral 
therapy for HCV. Voluntary licenses for sofosbuvir, daclatasvir, velpatasvir and volixaprevir have 
the potential to bring DAA costs into an affordable range, and DAA costs have already fallen 
substantially in many high-burden, low income countries such as Pakistan and India. There is still 
a risk that heavily burdened upper-middle income countries in the region (eg, China, Malaysia, 
Thailand) may be unable to benefit from generic competition but also are unable to afford 
higher prices. The extension of Gilead’s voluntary license to Malaysia, which might have been 
accelerated by the threat of a compulsory license, is a positive move toward addressing the 
problem of accessibility and affordability. However, in China mainland, only a few DAAs have 
been recently approved and are available, and their high cost has precluded them from wide 
coverage in the basic social health insurance program. So far only a few provinces have included 
the DAAs in their list of medications for reimbursement.  
 
Where available, provision of DAA regimens will likely require task shifting of treatment from 
specialised facilities to primary care. One example of expanded access to primary care has been 
in Bangladesh, where the Directorate General of Health Services has developed a module to 
train government physicians in the management of viral hepatitis. To date more than 3,000 
physicians have been trained.  
 
NGOs have an important role to play in advocacy for patients with hepatitis throughout the 
region. Notable achievements include those of the CFHPC, which is a national level public 
welfare foundation with strong social influence that has been working for 20 years to improve 
the general level of health in China by raising funds, acquiring supplies, and organising public 
welfare activities. Yiyou Liver Center, an NGO founded in 2013 by Chuang Lei, who has hepatitis 
B, aims to safeguard equal rights for those infected with HBV, and has been instrumental in 
achieving changes in policy by uniting with other stakeholders and utilising social media. Their 
advocacy efforts toward reducing drug prices and inclusion of TDF for HBV and DDAs for HCV in 
medication reimbursement lists have been successful at the national (TDF) level and regional 
(DAAs) level.  NGOs and civil society will need to play a bigger role with respect to elimination 
efforts in the future. 
 
 
Barriers to elimination [H3] 
 
Despite the overall high burden of disease, there are great disparities in the Asian governmental 
responses to the viral hepatitis epidemic. Common challenges to elimination include insufficient 
public awareness of risk factors and modes of transmission, leading to under diagnosis; high 
rates of transmission through medical exposures; limited access to care for PWID; prevailing 
stigma and discrimination against people infected with hepatitis viruses; and financial barriers to 
treatment and care285. The CEVHAP 186 analysis of national policies on chronic viral hepatitis 
identified areas requiring focus, including a need for strategic policy, availability of routine data, 
prevention strategies, clinical management and cost or availability of effective treatment. All 
countries and territories, with the exception of Hong Kong, have or are in the process of 
developing national strategic plans to eliminate viral hepatitis in line with WHO targets (table 
xx). However, budget allocation towards implementation of these plans is still to be confirmed 
in a majority of countries and territories.  
 
Stigma around a diagnosis of viral hepatitis is prevalent in Asia and needs to be overcome. In 
many countries and cultures, HBV and HCV infections are considered death sentences due to a 
lack of awareness among the public and, in many cases, health care workers. Many   countries 
or territories in Asia lack legislation to protect against discrimination among people with chronic 
viral hepatitis, and many countries criminalise drug use (Table 5.1). Only Japan, Hong Kong or 
Taiwan have some legal framework to protect those diagnosed with hepatitis against 
discrimination. Japan has a Basic Act on Measures against Hepatitis, which outlines how to 
protect people with chronic viral hepatitis from discrimination, and Hong Kong and Taiwan have 
general laws to protect citizens with hepatitis against discrimination186. Discrimination against 
people with chronic HBV infection still exists, particularly among less well-educated 
individuals187. To protect rights to education and employment, since 2010, tests for HBV 
infection at recruitment of students and employees have been banned in mainland China.  
 
There are fewer success stories among PWID, which comprises a population of at least 2.8m in 
Asia188 189. For example, Malaysia and China are among the few countries in Asia to implement a 
methadone substitution programme for PWID190.  
 
Despite recent initiatives, many countries in Asia have high rates of unsafe medical injections, 
with 75% of injections considered unsafe based on re-use of needles and syringes191,192. Pakistan 
is estimated to have the highest use of therapeutic injections in the world at 13-14 injections per 
person per year (compared to the WHO standard of 1-2 injections per person per year193). The 
high rate of medical injections, alongside other risk factors such as blood transfusions, dental 
treatments and individual risk behaviours like tattooing191,  has contributed to an estimated 
150,000-200,000 new HCV infections each year in Pakistan191 These challenges are shared in 
many other countries in the region194. 
 
Access to treatment is also a major issue in Asia, as the cost of drugs and diagnostics are often 
not covered by government programmes and remain largely out-of-pocket expense for many 
individuals, particularly in high-burden, low-income countries 195,196. Moreover, in many 
countries there is a disparity between urban and rural populations in terms of access to 
diagnostics and treatment197.  
 
Key priorities for action 
 
Despite the diversity of the region in terms of both the burden of viral hepatitis and economics, 
there are common challenges that could affect many country’s efforts to eliminate HBV and HCV 
by 2030.  
 
Although many countries have shown a clear commitment to seriously engage in elimination 
efforts, much work is needed to achieve political engagement, particularly in high-burden, low-
income countries. So far, no lower-middle income countries in Asia have embarked on 
treatment programmes similar to that developed in Egypt. Several possible reasons for political 
inaction include a poor understanding of the disease burden (due in part to lack of high-quality 
sero-surveillance data), and of the health and economic repercussions of inaction (due to lack of 
investment case analyses). Although national action plans exist or are being developed in many 
countries, the budgetary commitments for their implementation often lag behind. 
 
Clearer investment cases are needed for governments to embark on ambitious elimination 
programmes. Studies on return on public sector investment in HBV prevention and treatment 
have been done in China and demonstrate that money spent on HBV will save money over the 
15-year horizon 198. Such estimates have been instrumental in helping China develop a policy for 
viral hepatitis control, and similar analyses need to be done more widely (including for HCV).  
 
Despite strong progress in HBV vaccine coverage, continued efforts are required to maintain and 
expand coverage. In South Korea, for example, declines in HBV prevalence have been slow 
despite implementation of universal vaccination in 1992 (only 32.5% of males received all three 
recommended doses of the vaccine in 2006-8, primarily because of a lack of public awareness 
about the necessity of vaccination199. Provision of the birth dose vaccine has also been 
problematic for various reasons, including a high proportion (nearly 40%) of home deliveries in 
some countries, GAVI’s insistence on providing only the pentavalent (childhood) vaccine to 
countries whose immunisation programmes it supports, and lack of HBV testing among 
pregnant women200. Continued investment is also required to ensure safe injection practices, 
which could prevent an estimated 2.7% of new HBV and 6% of new HCV infections each year289. 
 
With regard to access to DAAs, immediate steps should be taken in Malaysia to facilitate 
extension of voluntary licensing agreements for generic manufacturers and, if possible, to 
extend this to other high burden upper-middle income countries in the region. In addition, 
voluntary licenses for shorter duration, pan-genotypic DAA regiments would be beneficial 
alongside greater efforts to ensure drugs are registered rapidly once available.   
 
In conclusion, Asia has the highest burden of viral hepatitis than any other region of the world 
and yet most infected individuals remain undiagnosed.The battle for elimination of viral 
hepatitis by 2030 will be won or lost in this region. Although there are already stories of 
significant success based on highly effective vaccinations campaigns against hepatitis B in some 
countries and availability of oral generic medications to treat both hepatitis B and C, challenges 
remain particularly in areas of nosocomial transmission of these infections on the one hand and 
wide access to medications on the other. Many governments of the region are still not fully 
engaged in the elimination effort and this requires substantially enhanced  advocacy in the 
region.   
 
 
Panel 4: Key priority areas for action for Asia 
 Increase political engagement in the elimination effort, particularly lower-
middle income countries within the region. 
 Support development of investment cases for governments that wish to 
embark on ambitious elimination programmes 
 Continue efforts to maintain and expand HBV vaccine coverage, with 
particular emphasis on maximising birth dose vaccination and prevention 
of mother-to-child transmission.  
 Control the spread of viral hepatitis through nosocomial means, 
particularly unsafe injection practices. 
 Capitalize on the availability of cheap generic medications in the region for 
treatment of both HBV and HCV and develop strategies to increase access 
significantly. 
 
 
Figure 6a The 10 countries with the greatest burden from viral hepatitis in Asia (data from 
Global Burden of Disease, 2016) 
Figure 6b Progress towards WHO elimination targets in the most heavily burdened countries 
of Asia (2017)   
  
Viral hepatitis in the Middle East and North Africa [H2]  
 
An estimated 15.5 million people in the Middle East and North Africa (MENA) are chronically 
infected with HBV, and 8.5 million with HCV201,202. Prevalence of HBV and HCV varies across the 
22 countries in the region; HBV prevalence ranges from 16%-19% in Mauritania and Somalia to 
0.5% in Bahrain (supplemental Table 4).  HCV prevalence in Egypt exceeds 6% (4.4% in those 
aged less than 60 years), which is higher than in any other country in the world203,204-209.201,210-213 
Egypt also dominates the region with respect to DALYs attributable to viral hepatitis (figure 7a). 
Of the estimated 6.6 million HCV-viraemic  below the age of 15 globally,214 820,000 (12.5%) live 
in the MENA region (supplemental table 5).214 More than 90% of people living with HBV and HCV 
infection live in low-income and middle-income countries in the region, including the North 
African countries (Algeria, Egypt, Libya, Mauritania, Morocco, Somalia and Sudan), Iraq, Syria, 
Turkey and Yemen. In these countries, folk practices and substandard health facilities remain 
the main causes of transmission.   
 
Programs to manage viral hepatitis and action plans for disease control and elimination vary 
widely between countries in the MENA region; most countries have a low prevalence of HBV 
and HCV, and viral hepatitis is not a top healthcare priority. Many countries have no quality 
epidemiological data, an essential step to identify needs and formulate a management plan, and 
most countries do not have a national plan or infrastructure in place for management. However, 
several countries in the region have made substantial progression path to elimination of viral 
hepatitis (Figure7b).  
 
Success stories and ongoing challenges [H3] 
 
The huge burden of HCV in Egypt and HBV in Saudi Arabia, and the efforts undertaken to  
control the epidemic and eliminate viral hepatitis are exemplary and illustrate how a well-
planned and executed national program can make a difference in population health and 
wellbeing.  
 
The high prevalence of HCV in Egypt has been attributed to mass treatment of schistosomiasis 
from the 1950s to the 1980s, in which shared, unsterile syringes and needles were used215,216. 
This represents the largest ever iatrogenic spread of blood-borne infection, with millions of 
people exposed to HCV, generating the high prevalence of HCV infection that remains today 
217,218. In 2006, the government of Egypt set up the National Committee for Control of Viral 
Hepatitis (NCCVH) to oversee the management of the HCV epidemic219,220 The NCCVH set a 
national strategy and established specialised treatment centres managed by qualified 
hepatologists. Through the program, treatment is paid for by the state, including full 
reimbursement for laboratory tests and treatment. In 2014, an action plan was developed aimed 
at reducing the national prevalence of HCV to <2% by 2025 and <1% by 2030, potentially 
preventing more than 250,000 deaths between 2015 and 2030 (Supplemental figure 5)221. As 
part of this plan, the NCCVH negotiated the price of DAAs down to 1% of the US price,222 without 
precluding local production of generics. The introduction of locally produced generics in late 
2015 reduced the cost of 12 weeks’ treatment with sofosbuvir and daclatasvir to about US$80, 
resulting in a massive treatment uptake of about 1m patients in 2016 and 2017219,223. As a result, 
Egypt is on the path to meet elimination targets for HCV by 2030 or even earlier. By May 2018, 
close to 2m patients with chronic hepatitis C had been treated with DAAs; the treatment rate 
has now exceeded 25% of the infected population.  
 
The program had to overcome several un-anticipated challenges during the first phases of its 
initiation, which serve as lessons for other countries in the region and elsewhere86 240. The initial 
challenge was management of the number of patients to be treated upon initiation of the 
program, estimated at 750,000 diagnosed patients, which required a web-based national patient 
management system. Given that supplies of medication were initially limited, patients had to be 
prioritised for treatment, starting with patients with advanced fibrosis or cirrhosis, which caused 
administrative and moral problems, and resulted in a backlog of hundreds of thousands of 
patients. With increased supply of medication and the introduction of generics, prioritisation 
ended. An ongoing challenge going forward is the identification of a sufficient number of 
patients needing treatment to achieve HCV elimination goals. Registration of new patients 
needing treatment has decreased from 300,000 during the first week of the program to less than 
10,000 patients per month in 2017. To address this, the Ministry of Health started a national 
screening program, initially targeted to individuals aged 16-25 years as a requirement for 
national identification cards and driver’s license, enrolment in university, and military service 
(for males). However, as HCV prevalence is lowest in this age group (<2%),203 more than 15m 
individuals would have to be screened to reach the number needed to be treated each year in 
the national plan (350,000), and identifying each patient will cost more than USD$50. As such, 
screening should be focused on populations with higher prevalence and risk, such as adults over 
age 40 years, PWID, and people who are incarcerated.  
 
Several factors contributed to the initial success of Egypt’s national HCV treatment program, 
including the availability of large scale epidemiological data, which defined the epidemic and 
drove sustained societal pressure for state-sponsored treatment. The availability of effective 
DAAs with excellent safety and tolerability profiles, the decreasing costs of brand medications at 
the outset of the program, and the approval and use of effective cheap local generic 
medications facilitated the escalation of the program. Although Egypt remains the country with 
the highest prevalence of HCV in children (1.08%), a dedicated paediatric program for treatment 
of HCV sets it apart from other countries in the region. To date, more than one thousand 
children aged 3 to 18 years have been treated with pegylated interferon through an NGO 
sponsored program. DAAs approved for children are currently being used in some centres but 
are yet to be introduced into the national treatment program . The NCCVH action plan also 
included guidelines for ensuring blood safety, injection safety, and strict infection control,224 
which were applied to a few model dialysis centres and were instrumental in reducing incidence 
and prevalence of HCV225, but they still need to be applied nationally.  
 
Saudi Arabia established a national committee in the 1980s, when the prevalence of HBsAg-
positive individuals neared one-quarter of adult males, more than 10% of females246, and 7% of 
children226. As part of the national plan, a vaccine program was launched in 1989227,with a catch-
up program to vaccinate all children at school entry, and vaccination of all healthcare workers 
and haemodialysis patients. As of October 2007, all people age 24 years or younger (~60% of the 
population28) had been vaccinated228, and vaccination coverage is now close to 100%;. The 
vaccination programs were coupled with strict national blood safety and healthcare infection 
control policies, including mandatory testing for HBV, HCV, and HIV as part of a compulsory 
premarital screening program, as well as recommended screening for HBsAg among pregnant 
women229, resulting in almost complete blood safety. As a result, the prevalence of HBV in Saudi 
Arabia has dropped substantially over the last two decades, with the virtual elimination of 
HBsAg among vaccinated children aged 1-12 years230,231. Saudi Arabia has already met and 
exceeded most of the WHO targets for elimination of hepatitis B for 2020 and 2030.  Pivotal to 
this success were the establishment of a highly empowered steering committee that included all 
concerned parties: researchers, clinicians, and ministry of health officials; epidemiology studies, 
and public and governmental acknowledgement of the problem.  
 
Limitations and Barriers to Elimination  
 
Most countries in the MENA region are low-income or middle-income countries that cannot 
afford to treat HCV-infected patients with DAAs or HBV patients with second generation 
nucleos(t)ide analogues if cheap generics are not available. This problem is magnified in 
countries with a relatively large disease burden (Mauritania, Somalia, Sudan, Syria and Yemen). 
Most other countries either can afford originator drugs or have access programs or affordable 
generics. The cost of HCV diagnostic tests is also increasing (the cost of diagnostic tests in 
Egypt’s national program now exceeds the cost of treatment), and there are no generic or 
locally produced diagnostic tests. Furthermore, multiple baseline and follow-up tests for HCV (as 
required in Egypt’s national plan) adds considerably to costs. Simplifying monitoring and follow-
up strategies, replacing RNA testing with HCV-cAg testing, and developing local diagnostic tests, 
could result in major cost savings.  
 
In countries with national plans in place, identification of a sufficient number of HCV-infected 
patients needing treatment is an ongoing challenge. Pro-active intervention to prevent 
transmission and new infection are also be required. Most ongoing transmission of HCV is in 
healthcare settings, and strict infection control standards must be enforced throughout 
government and private healthcare settings. The growing size of the youth population in the 
MENA region (160 million people aged 14 years or less) represents another potential barrier to 
HCV elimination, and prevention, diagnosis and management of HCV at an early age is essential. 
 
 
Panel 5: Key priorities for action in the MENA region 
 Conduct epidemiology studies to identify the burden of viral hepatitis in countries 
lacking data.  
 
 Establish national plans for HBV and HCV elimination where needed. 
 
 Ensure HBV birth dose vaccine implementation in all countries, and increase 
coverage in countries without universal coverage. Improve third-dose vaccine 
coverage in countries with <95% coverage 
 
 Restore vaccine programs that have been disrupted due to conflict. 
 
 Implement maternal screening for HBV in all countries.  
 
 Implement vaccination programs for refugees and migrant children. 
 
 Implement and monitor strict infection control policies. 
 
 Improve access to affordable antiviral drugs, including provision of generics. 
 
 Improve identification of individuals with HCV in Egypt needing treatment through 
targeted screening. 
 
Figure 7a The 10 countries with the greatest burden from viral hepatitis in MENA region (data 
from Global Burden of Disease, 2016) 
Figure 7b Progress towards WHO elimination targets in the most heavily burdened countries 
of MENA region (2017)
 5.3 Elimination in the Americas 
 
The Americas account for just under 10% of both deaths and DALYs attributed to viral hepatitis 
globally.  In contrast to Asia, HCV is the greatest challenge to public health in the region, accounting 
for 70-80% of hepatitis related deaths (figure 10a). The USA, Brazil and Mexico account for 
approximately half of the regional disease burden (figure 10a). An estimated 2.7-3.5 million people 
live with chronic HCV in the USA alone 232. In 2007, the number of HCV-related deaths exceeded 
those of HIV/AIDS-related for the first time, with most new HCV infections linked to injection drug 
use. In Brazil, 1.5-2 million people are infected with  HCV201,233 234, which remains the leading cause 
of cirrhosis and  hepatocellular carcinoma in the country235. The USA and Brazil, which have similar 
burdens of disease but very different economic resources (per capita income of USA is 
approximately 6 times higher), have both made important steps towards elimination that serve as an 
example for other countries in the region.  
 
Successes and ongoing challenges 
 
All countries in the region have included HBV vaccination in their official immunisation schedules, 
and many countries have adopted nationwide birth-dose HBV vaccination236, representing over 90% 
of births within the region, although this is not yet widely implemented in Canada. The USA and 
Brazil have achieved high coverage of HBV vaccination; coverage in Mexico appears to have fallen 
slightly in recent years (82% in 2015), but the coverage of birth-dose vaccination is consistently high 
(98% in 2015, compared to 72% in USA).  A number of countries including Argentina, Brazil, Peru and 
the USA, have extended vaccination to older groups and have implemented catch up vaccination 
campaigns236.  
 
The impact of HBV vaccination has been seen throughout the region. There has been a marked drop 
in the incidence of acute HBV in the general US population, now estimated at 0.9/100,000 persons,  
and among underserved communities. For example, HBV was endemic in the 1970s among the 
Alaska Native People (HBsAg prevalence of 3-8%)237, but a comprehensive screening and vaccination 
programme in the 1980s reduced transmission from over 200 symptomatic cases/100,000 to nil. 
Annual incidence in this population is now <1/100,000, and no child under 20 is known to have 
chronic HBV238. Substantial declines in childhood HBsAg prevalence have also been documented in 
Peru 239, Colombia  240, and Canada 241. Vaccination efforts in Brazil have resulted in a change in the 
country’s HBV endemnicity status from intermediate to low242. However, there remain marked 
regional differences4,6 with particularly high HBsAg prevalences (up to 6.2%) in areas of the 
Amazon243. In the USA, 84%-88% of pregnant women are tested for HBsAg. Despite this, an 
estimated 800-1000 infants are infected at birth244. As many of these infections constitute a failure 
to vaccinate infants born to mothers with high viral load, US guidelines now suggest maternal 
antiviral treatment for those with HBV levels above 200,000 IU/ml245.  
 
Brazil has shown strong political leadership in tackling hepatitis C. Brazil integrated the Viral 
Hepatitis National Program with the National STD/AIDS Department in 2009, has sought to include 
viral hepatitis in the public health program (Sistema Unico de Saude), and periodically publishes 
guidelines for viral hepatitis management in the country 246-248. In 2015, DAA therapy was made 
available, although as of early 2018, DAA therapy was limited to those with significant fibrosis or 
high risk of complications 248. In 2011, the government implemented rapid HCV testing, with around 
3 million tests done annually in the last few years249, as compared to estimates of 20,000 HCV 
infected patients diagnosed annually and as few as 10,000 treated each year in 2013 234 250. Falling 
drug prices are expected to make treatment more widely available, with over 60,000 patients 
already receiving DAA treatment between 2015-7.  
 
In the USA, one-time HCV testing is recommended for people born between 1945 and 1965, as an 
estimated 75% of all HCV infected people in the USA were born during those years. Such birth cohort 
testing is cost effective and identifies relatively high proportions of HCV-infected individuals; 
however, implementation of this strategy has been limited and requires increased professional 
education and technologies to integrate testing into routine health care251,25238. Advocacy for this 
approach is emerging elsewhere in the region, including Canada and Brazil253. Monitoring the 
success of this testing programme and promoting similar programmes is vital for progress. 
 
 
Barriers to Elimination 
 
Injection drug use is a major barrier to elimination efforts in the USA. New HCV infections in the USA 
doubled from 2010 to 2015, most dramatically among young adults with a history of injection drug 
and opioid agonist (eg, oxycodone) use. Injection drug use is also responsible for a 21% increase in 
HBV incidence in the USA in 2015. Reductions of HCV incidence have been documented among 
PWID254, and this population is an ongoing focus of prevention efforts. The US prison population is 
another major barrier to elimination efforts. Over one million persons are incarcerated in the USA at 
any given time with limited access to healthcare, including hepatitis testing and treatment. 255 
Testing and treatment for HCV in corrections facilities represents an enormous opportunity to 
achieve elimination goals256,257.  
 
The USA, Brazil and Canada share the challenge of providing equitable access to health across 
extensive, varied geographical regions, with rural populations often living long distances from heath 
care services. In the USA, this creates a particular problem in tackling the rural opioid epidemic, with 
an estimated 80% of all  HCV-infected people  aged less than 30 years living more than 10 miles from 
a syringe service program258. This situation underscores the importance of combating the rural 
opioid epidemic using diverse strategies, including integration of HCV testing and treatment services 
into syringe services programs, and designating pharmacies as sources of safe injection equipment.  
 
In Brazil, major geographical, social and economical disparities exist among the different regions of 
the country, creating inequities in access to care, especially for subpopulations residing in 
underserved areas of the North, Northeast and Midwest areas such as the Amazon basin. These 
inequities include limited access to a specialist who can provide DAA therapy (currently available in 
only a few centres in Brazil), often resulting in long delays between diagnosis and initiation of 
therapy. The paucity of specialist care is also a challenge for retention in care; a study conducted in 
Southeast Brazil found that 22.1% of anti-HCV-positive patients in the region were lost to follow-up 
(lapse of more than 1-year since the last clinical appointment) 259. And despite increased HCV testing 
in Brazil, the proportion of those diagnosed remains low234,250.  
 
In the USA, disparities in health insurance coverage constitutes a substantial barrier to care and 
treatment for viral hepatitis, despite improvements associated with implementation of the US 
Affordable Care Act. In states that have expanded Medicaid, access to prevention, screening and 
care services has improved for low-income individuals260. Even for individuals who have health 
insurance, national HCV testing recommendations have not been incorporated into primary care and 
other settings in which at-risk patients could be offered HCV testing33. This gap is reflected by the 
low (~50-60%) awareness of HCV infection in USA 261. Furthermore, many primary care clinicians in 
the USA remain unprepared to provide DAA treatment, a problem that can be rectified through 
increased education (including for pharmacists and other mid-level providers) and development of 
simplified care algorithms.  
 
As in other regions, migration from countries with high HBV endemicity poses a challenge to 
elimination in the USA and Canada, with an estimated 54,000 persons with chronic HBV migrating to 
the USA in 2004-8262, roughly half of whom were born in Asia. As a result, the USA recommends (but 
does not mandate) HBV testing for those born in countries with a >2% HBsAg prevalence.  
 
Incomplete epidemiological and surveillance data is another major impediment to achieving 
elimination goals in the USA. At present there are insufficient resources to provide the case 
surveillance data needed to monitor the number of HBV infected people. As most states that have 
adopted requirements for reporting HCV test results lack the capacity to investigate acute cases, 
develop case registries, and collect longitudinal data to monitor the cascade of care. A panel recently 
commissioned by the US National Academies of Science, Engineering, and Medicine recommended 
that the Centers for Disease Control (CDC) work with state and local health departments to support 
monitoring of all HCV cases reported to public health surveillance, and that the CDC conduct 
serologic surveys of high risk populations263, an endeavour that could be facilitated by leveraging 
existing HIV/HCV and cancer registries264 and electronic clinical care data99. However, additional 
funding is sorely needed to measure the effect of these initiatives in term of progress toward 
elimination goals, and to identify the areas on which to focus the limited public health resources 
 
Costs of testing and therapy remain a barrier to access throughout Latin America; in 2017 only 12 of 
20 countries reported offering free testing for HCV, and a majority of countries did lacked access to 
DAAs 265 . The Pan American Health Organisation’s strategic fund has incorporated DAAs as of 2017, 
which allows pooled procurement of essential medicines and strategic health supplies. The fund is 
able to supply interest free credit lines to countries, Colombia being among those who have used 
them 265.  
 
  
Figure 8a The 10 countries with the greatest burden from viral hepatitis in the Americas (data from 
Global Burden of Disease, 2016) 
Figure 8b Progress towards WHO elimination targets in the most heavily burdened countries of 
the Americas (2017) 
 
 
Panel 6: Key priorities for action in the Americas region 
 Ensuring adequate resources for surveillance and data collection systems to monitor 
and evaluate progress towards elimination goals 
 Elimination targets in for HBV in the US need to take account of the significant 
contribution to new infections from migration  
 Ensure a greater focus on access to care and treatment for incarcerated 
populations, particularly in US 
 Support the development of decentralised services and prescribing by non-specialist 
services will be particularly important in reaching underserved populations far from 
large urban centres 
 Ensure countries throughout the region can use existing mechanisms to ensure 
procurement of affordable medicines (e.g. using PAHO) 
 
  
Viral hepatitis in the European Union [H2]  
The burden of viral hepatitis in the 28 member states of the European Union (EU) varies significantly 
from country to country, but is greatest in Italy and Germany (figure 11a). A relatively high 
prevalence of viral hepatitis in new member states have added to the overall regional disease 
burden.  
 
In 2016, the prevalence of chronic hepatitis B in the EU was estimated at 0.89% (4.5m individuals), 
with country level HBsAg prevalence ranging from 0.1% to 5.5%266. HBV vaccination in the EU 
countries started in the 1990s, although Denmark, Finland, Hungary, and Slovenia do not provide 
universal infant vaccination nor do they report vaccination data. The UK added the HBV vaccine to 
infant vaccination schedules in 2017. The prevalence of HBsAg among children aged 5 years was 
0.11% in 201612; over two-thirds of these cases are in Italy, Poland, UK, Romania, Germany, and 
Greece. Only 11 countries in the EU (of 23 that provided data) reported three-dose vaccination 
coverage levels of 95% or higher in 2015 (supplemental figure 6) 125.  
 
In 2015, the prevalence of HCV in the EU was estimated at 0.64% (95% uncertainty interval 41-74%) 
corresponding to 3,238,000 (2,106,000-3,795,000) RNA positive infections267. The highest burden of 
the disease in the EU is found in Italy, Spain, Germany, Romania, France and the UK. Nine countries 
(Italy, Romania, Spain, Germany, France, the UK, Poland, Greece, and Bulgaria) account for more 
than 80% of the total viraemic HCV infections in the region.  
 
In Europe, as in other regions, HCV is now transmitted primarily among PWID31 and there is a higher 
prevalence amongst prisoners, migrants and the homeless compared with the general population268. 
The pooled estimates of the percentage of PWID who are young (age <25 years), have unstable 
housing or were homeless, a history of police arrest or incarceration, and engage in sex work 
highlight the patterns and prevalence of drug use and the underlying socio-demographic factors, all 
of which contribute to higher risk of HCV infection26. Historical use of improperly sterilised needles 
with subsequent transmission might account for the higher burden of disease in Southern Europe 
particularly Italy, Spain and Romania. Most of the patients infected in Europe are age 45 to 60 years 
old, suggesting a possible target birth-cohort group for screening programmes.  
 
In the WHO Euro region, an estimated 14% of all HBV infections are diagnosed125, but current 
estimates on the percentage of those who are treated are inconclusive. Over a third of HCV 
infections in the EU have been diagnosed, but there is considerable variability; more than 70% of 
infections in Sweden, Malta, Finland and France are diagnosed compared to less than 20% in 
Bulgaria, Lithuania, Poland, and Slovakia.  In a 2013 WHO survey in 25 EU and European Economic 
Area (EEA) Member States, all countries reported having a national surveillance system for acute 
HBV and 23 reported having a surveillance system for acute HCV. National surveillance systems for 
chronic HBV and HCV infection were reported by 18 countries and 17 countries, respectively269.  
 
Europe has well characterised cohorts with HCV-HIV co-infection270. Data from the EuroSIDA HIV 
infected observational cohorts show that the prevalence of anti-HCV varies: in Eastern and Southern 
Europe (where HIV is frequently acquired via injection drug use), 58% and 29% of patients are anti-
HCV antibody positive, respectively, and modelling suggests that eliminating HCV from HIV-positive 
populations will be possible271. In Northern and Western Europe (where sexual transmission among 
MSM is the major route of HIV transmission), 17% and 20% are anti-HCV antibody positive 
respectively272. In both settings, HIV-positive MSM appear to be accessible and motivated to receive 
HCV treatment. Thus engagement with well-established HIV services presents a key opportunity for 
microelimination70,273.  However, it remains to be seen whether changes in sexual behaviour as a 
consequence of more widespread access to HIV pre-exposure prophylaxis will alter HCV transmission 
274.  
 
Success stories and ongoing challenges [H3]  
 
The EU is strategically placed to work toward elimination of HBV and HCV, given the existence of 
relatively strong public health systems and, in some countries such as Spain, Portugal, Iceland, and 
Scotland, strong political commitment towards elimination.  Notable success has been obtained in 
implementing HBV vaccination, and treatment of individuals diagnosed with HBV. Western European 
regions have shown small declines in HCV prevalence128; in Spain and Portugal, more than five 5 
times more people reached SVR than there were new infections in 2016128. In Portugal, the efforts of 
civil society and academic stakeholders have resulted in a consensus on the need for an overall focus 
on policies for HCV elimination and prevention, financing, access models, a national action plan and 
a central patient registry. In addition, programs that ensure access to clean injection equipment, and 
changes in social and political attitudes that eschew punitive measures for drug users have increased 
treatment rates. Access to treatment remains unequal across the EU, however; approximately 
146,000 (4%) of 3.4 million people with chronic HCV in the EU were treated in 2015, with Spain, Italy, 
Germany, France, and the UK accounting for more than 80% of those treated whereas less than one 
percent 1% were treated in Bulgaria, Croatia, Malta, and Romania. 
 
Scotland serves as a model EU country with well-developed linked data systems providing 
comprehensive epidemiological information on HCV to support policy initiatives, with funding for 
diagnosis and implementation. For example, using the nationwide Scottish registry of HCV treated 
patients, examined those achieving SVR between 1997 and 2016 and found that the apparently 
higher incidence of HCC after DAA therapy might be explained in part by differences in clinical 
characteristics of groups receiving different treatments275. The UK clinical and public health systems 
are providing some of the strongest evidence of the success of DAAs on the clinical burden challenge 
of HCV 276-278. 
 
Barriers to elimination [H3] 
 
Immigration represents a particular challenge for elimination efforts in the EU. In 2010, 47.3 million 
people living in the EU were born outside their resident countries. Limited data indicates that 
prevalence of HBV and HCV is higher in migrants to the EU and the European Economic Area (EEA) 
countries (the EU plus Iceland, Liechtenstein and Norway) compared to the population as a whole, 
reflecting prevalence rates in their countries of birth279. The number of new HCV infections in the EU 
is estimated at 57,900 (43,900-67,300) per year, with another 30,400 (26,600-42,500) new infections 
diagnosed amongst migrant populations201. An estimated 1-2 million migrants to Europe have 
chronic hepatitis B.280 Migrants therefore are a key group for case finding and treatment and 
constitute an important relative contribution to prevalence of viral hepatitis, although the 
proportion varies from country to country. For example, there were an estimated 480 new chronic 
HBV infections within Germany in 2015, with an additional 17,800 new cases through immigration in 
the same year279.. 
 
Most newly acquired  chronic HBV infections are perinatal266,281, and the prevalence of HBV among 
women of child bearing age is highest among immigrant populations280 . There is no uniform policy 
for antiviral prophylaxis for highly viraemic mothers to reduce the risk of mother to infant 
transmission in the EU, an area that needs to be addressed in guidelines. 
 
Injection drug use remains central to the epidemic in the EU282. In 2016, the European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA) estimated the percentage of high-risk opioid users 
receiving opioid substitution therapy in 23 EU/EEA countries, which ranged from 8% in both Latvia 
and Slovakia to more than 75% in France and Luxembourg. Only 10 countries had high intervention 
coverage as defined by the threshold of greater than 50% of the target population, and only six of 
the 15 EU/EEA countries with available data could be categorised as high-coverage countries, 
defined as more than 200 syringes per PWID distributed per year283. In seven countries, less than 
30% of the target population was estimated to be receiving OST283. As in other parts of the world, 
OST and (particularly) NSP are reported to be less available in prisons in EU/EEA countries. Access to 
community testing, psychiatric or addiction services, harm reduction assistance and social care 
resources are variable, as are policy responses 284. 
 
Differences between the autonomous health care systems of the EU prevent harmonised policies 
and the EU has not sought to align national laws and policies for the management of viral hepatitis.  
Although Joint Procurement Agreements for pandemic vaccines are in place, supranational 
procurement or price convergence of tests, devices and antiviral therapies have not materialised 
because of divergent national policies and budgets.  
 
The Action plan for the health sector response to viral hepatitis in the WHO European Region, 
endorsed by the WHO European Regional Committee in September 2016, adopts the WHO global 
viral hepatitis elimination targets regarding HBV and HCV transmission and mortality285. Though 
several countries have developed strategies, not all have and regional targets will be much more 
achievable when this national policy infrastructure is in place throughout the EU.    
 
Panel 7: Key priorities for action in the EU 
 A cohesive regional European strategy for coordination of data, context-based 
screening and drug procurement should be adopted 
 Countries should develop costed elimination delivery plans, and ensure that 
appropriate resources are in place to provide access. 
 HCV screening, treatment, and harm reduction programmes among high-risk 
groups, including PWID, incarcerated individuals, and MSM should be strengthened  
 Migrant populations should have access to national health and insurance services, 
with efforts to remove stigmatising inferences.  
 More widespread adoption of decentralized care and implement point-of-care 
testing in high-prevalence environments (prisons, addiction centres, and regions 
with particularly high disease prevalence) 
 
Figure 9a The 10 countries with the greatest burden from viral hepatitis in the EU (data from 
Global Burden of Disease, 2016) 
Figure 9b Progress towards WHO elimination targets in the most heavily burdened countries of 
the EU (2017) 
 
 
 
  
Viral hepatitis in Sub-Saharan Africa [H2] 
 
HBV is endemic in Sub-Saharan Africa with approximately 60 million people chronically infected, of which 
1.96 million are HIV co-infected270,286.  WHO estimates the prevalence of HBsAg at 6.1% to 8.8%287.  The 
burden of HCV is also significant, with approximately 10 million infected.  In West and Central Africa, 5.7% 
are coinfected with HCV and HIV288,289.  HBV and HCV infection in the 10 most heavily burdened SSA 
countries account for approximately 200 000 deaths annually, equating to just under one-fifth of the 
global mortality9. HBV alone is implicated in more than half of liver cirrhosis and three-quarters of 
hepatocellular carcinoma cases290. 
 
New highly effective treatments, innovative diagnostics and the new global political landscape focused on 
hepatitis, make elimination of viral hepatitis in SSA feasible.  Many countries are developing national viral 
hepatitis plans, and some countries already have such plans (figure 10b). Nonetheless, WHO targets are 
formidable in a region comprising 47 countries with a mean per capita GNI of less than $1657 USD and a 
total health expenditure of only 5.5% of GDP291. Many countries in SSA share healthcare challenges related 
to large rural populations, poor health infrastructure, shortages of healthcare personnel, and endemic 
infectious diseases including malaria, tuberculosis and HIV/AIDS. 
 
The establishment of robust national viral hepatitis plans to guide implementation strategies is the first 
major step towards demonstrating political commitment at a country level. In 2016, only 1.1 million HBV-
infected individuals had been diagnosed (0.1% to 4% with the highest rate in the Eastern SSA) and 33,000 
were estimated to be treated, which equates to less than 1% of those eligible. Almost no countries have 
initiated large scale screening programmes for HCV and most infected individuals remain undiagnosed.  
Apart from Rwanda, access to therapy is limited. As of December 2017, only seven countries in SSA had 
developed a costed hepatitis plan (Ghana, Nigeria, Ethiopia, Cote d’Ivoire, Senegal, South Africa and 
Mauritania) whereas 15 other countries (including Cameroon, Tanzania,  Democratic Republic of Congo 
and Tanzania) had drafts in various phases of development. The lack of detailed and reliable HBV and HCV 
sero-epidemiological data in many parts of sub-Saharan Africa despite existing data suggesting 
considerable burden. This hampers planning but must not be used as an excuse to retard implementation. 
 
 
Success stories and ongoing challenges [H3] 
 
Rwanda was one of the first countries in SSA to establish a national viral hepatitis control programme, 
initiated in 2012 and built on the existing HIV infrastructure.  The Rwandan comprehensive community 
health system offers near universal (>90%) health insurance coverage, and government partnerships have 
enabled access to subsidised therapy for HCV and HBV. By the end of 2017, over 2000 people had started 
curative HCV treatment using a simplified DAA regimen approach292. In 2017, the Rwandan Biomedical 
Centre embarked on a campaign of  vaccination, screening and confirmation, identifying an estimated 
9,000 HCV-infected individuals and 722 HBV-infected individuals that needed to be linked to care and 
treatment. As of early 2018, free HBV and HCV treatment and assessment of viral load is now offered to all 
Rwandan citizens, whereas free treatment was previously offered only to certain Rwandans depending on 
social stratification category. Rwanda illustrates that the incorporation of viral hepatitis and HIV into the 
package of essential health services can be successful  provided governmental commitment to 
strengthening of health infrastructure and provision of adequate financing for compulsory health 
insurance. 
 
The testing of blood products for transmissible infection has improved significantly in SSA. 40 WHO Africa 
countries in SSA, now report testing 100% of all blood donations for all transfusion-transmitted 
infections293, although overall coverage is still lower than other regions.  
 
Barriers to elimination [H3] 
Horizontal transmission in childhood is the predominant route of HBV transmission in SSA, responsible  for 
~ 90% of chronic HBV infections. The annual number of HBV perinatal infections  is estimated to be twice 
that of HIV perinatal infections, indicating that identifying women at risk of transmitting the infection to 
their infants is crucial to preventing mother-to-child transmission294,295.  
 
By 2017, only nine countries in SSA had implemented the birth dose vaccine, and HBV vaccine coverage is 
only 77%. Implementation is a challenge in a region where many births occur outside health facilities (40-
50% of deliveries in Uganda and Nigeria). Additional barriers to providing the birth-dose vaccine in SSA 
include cost, because funding from Gavi was not available for the monovalent HBV birth-dose vaccine; 
vaccine stock-outs; transporting and administering the vaccine in the setting of home-births; concerns 
about vaccine storage outside the cold chain; and cultural factors such as waiting until after a child’s 
naming day (around 7 days) to bring him/her to a healthcare facility for vaccination. 296 
 
Strategies ensuring universal coverage and timely administration of HBV birth dose vaccines, such as 
pregnancy tracking, using pre-filled auto-disposable devices (eg, UnijectTM) and use of community 
healthcare workers to administer the vaccine have been successfully used in Vietnam, Indonesia and 
China297-299 and require evaluation in SSA. Integration of the birth dose vaccine into an early postnatal care 
package that includes home visits within one day of home birth, as recommended by WHO and UNICEF, 
would have the dual benefit of improving newborn survival and reducing long-term HBV mortality300.  
Introduction of monovalent HBV birth-dose vaccine within 24 hours of delivery, coupled with the 
identification and treatment of HBV infected mothers, are critical to elimination of HBV, and should be a 
priority for the region73 301. 
 
Injection drug use is a barrier to elimination efforts in SSA, as elsewhere. 8% of PWID globally are 
estimated to live in SSA302.. However, few countries have government supported NSP or OSP303, and 
discrimination against and stigma amongst these high-risk individuals is not challenged. Furthermore, 
vulnerable or marginalised groups, such as MSM and PWID, risk criminal prosecution given 
thathomosexuality is illegal in several SSA countries.     
 
Another major barrier to elimination in SSA is the lack of awareness about viral hepatitis among 
both patients and healthcare workers. Data from West Africa reported that <1% of participants 
knew of their hepatitis B status81, and healthcare workers often lack adequate knowledge of viral 
hepatitis, in stark contrast with their HIV knowledge304.  Screening efforts in this region should 
focus on a targeted approach, for example by testing for HBV at antenatal visits. For HCV, 
screening should focus on individuals who have received blood or blood products, PWID, MSM, 
healthcare workers, recipients of intramuscular antimony injections (due to unsafe injections) and 
recipients of traditional practices involving parenteral inoculation, such as scarification and adult 
circumcision. 
 
Due to the poor government healthcare infrastructure and financing, out-of-pocket expenditure 
in both public and private health facilities constitutes over 60% of total health expenditure in 
most of Western Africa305, as compared to less than 20% in Southern African countries such as 
South Africa, Namibia, Mozambique and Botswana, where government healthcare financing is 
greater306. Even with falling prices for viral hepatitis therapy, treatment and diagnostics remains 
unaffordable for many people in the region.    
 
Only 3% of the global healthcare workforce resides in SSA and this shortage hinders the equitable 
delivery of healthcare, including for viral hepatitis. International migration, attrition, training 
shortfalls relative to population growth, and poor remuneration and working conditions 
contribute to these shortages307. WHO estimates that 4.3 million healthcare workers are needed 
to fill this gap in 57 countries in Africa and Asia308. Expedited training of middle-level healthcare 
medical, nursing and laboratory personnel is required for healthcare in general. With the 
development of new rapid diagnostics and mobile health technologies, community healthcare 
workers are increasingly providing services in rural and underserved communities, especially in 
maternal health and HIV services. Evaluating simplified models of care that can be delivered 
through community healthcare workers is a high priority in SSA309,310.  
 
A public health approach has been successful in managing the HIV/AIDS pandemic, and this 
should now be adopted for viral hepatitis. HIV treatment programmes are established in many 
countries and provide universal free HIV care for persons in peri-urban and urban areas. These 
treatment programmes provide disease specific infrastructure, operate their own supply chain, 
provide subsidised medication and have established monitoring, evaluation and national 
surveillance systems specific for HIV with substantive funding from PEPFAR, Global Fund and 
other global donors. With the decline in donor funding, the establishment of viral hepatitis 
programmes within the context of universal healthcare is currently being advocated by WHO, is 
supported by many countries within SSA and is essential to achieve the viral hepatitis elimination 
targets311. 
 
 
 
 
Panel 8: Key priorities for action in SSA 
 Efforts should continue to ensure full vaccine coverage and ensure universal 
implementation of HBV birth dose vaccine within 24 hours of delivery  
 Universal antenatal screening for HBsAg needs to be prioritized  
 Affordable quality nucleic acid tests (NAT) need to be widely available , for both HBV 
and HCV 
 There needs to be sustainable access to treatment for HBV mono-infected 
individuals, not just those with HBV/HIV co-infection 
 There is a need for education programmes around HBV and HCV to decrease public 
stigma around viral hepatitis 
 Community based activist or support groups need to mobilise to support viral 
hepatitis programmes 
 Decriminalise high risk groups e.g. MSM, PWI(U)D  
 
Figure 10a The 10 countries with the greatest burden from viral hepatitis in sub-Saharan Africa 
(data from Global Burden of Disease, 2016) 
Figure 10b Progress towards WHO elimination targets in the most heavily burdened countries of 
the SSA (2017) 
  
5.6 Viral hepatitis in Eastern Europe and Central Asia [H2] 
 
The Eastern Europe and Central Asia (EECA) region is one of the most heavily affected by viral 
hepatitis and HIV. The HCV epidemic is growing, with an estimated 11.3 million HCV seropositive 
individuals in the region1 and a particularly high prevalence of viral hepatitis-HIV co-infection among 
PWID270.  
 
As in SSA, there is a lack of reliable epidemiological data on viral hepatitis in a majority of EECA 
countries due to an absence of national registers and large-scale testing campaigns or studies.312 
HCV prevalence estimates among the general population range from 1.2% (Kazakhstan) to 8-12 % 
(Ukraine). HBV prevalence estimates range from 0.04% (Tajikistan) to 8% (Uzbekistan), although the 
low reported prevalence in Tajikistan likely reflects low quality surveillance data. HBV vaccination is 
supported by governments and/or international organisations (eg, GAVI, UNICEF) in a majority of 
surveyed countries, and average coverage is 89%. However, vaccine coverage ranges widely, with 
some regions having very low coverage (eg, 28.8% in Ukraine). Available data about annual HBV-
related and HCV-related mortality rates are thought to be underestimates due to their widespread 
under-documentation on death certificates. Very few data are available on viral hepatitis related 
mortality, but a study in Russia estimated that PWID aged less than 30 years account for 80% of all 
HBV-related deaths2.  
 
An estimated 3.1 million PWID live in the region (1.8 million in Russia alone), and there is limited or 
no access to prevention services for PWID in this region. Injecting drug use remains the primary 
driving force for both HIV and HCV epidemics. HCV prevalence among PWID ranges from 20.9% 
(Uzbekistan) to 70-95% (Belarus), a high proportion of whom are also infected with HIV (as high as 
98% in some areas of Russian Federation). HBV prevalence among PWID ranges from 0.1% (Belarus) 
to 56% (Kyrgyzstan). For HCV, PWID are specified as a key population in national plans and 
guidelines in all countries. MSM, healthcare workers, and patients undergoing invasive/hospital-level 
procedures are specified in national plans of 10 countries. The EECA region has low coverage of 
antiretroviral therapy (ART), estimated at 21%, meaning those living with HIV are particularly 
vulnerable to accelerated liver disease progression.  
  
Success stories and ongoing challenges [H3] 
 
Georgia has become a regional and international leader in HCV national elimination efforts, with an 
implemented strategy resulting from the joint efforts of civil society and NGOs, strong political will of 
the state authorities, and financial and technical support of international donors (CDC) and industry 
(Gilead). HCV RNA prevalence in Georgia is estimated at 5.4% (approximately 150,000 individuals), 
and the majority (57%) of infected individuals acquired infection from injection drug use, although 
there are also a substantial number of infections amongst MSM (7.1-18.9%) and healthcare workers 
(5%). Treatment for HCV is freely available within the National HCV Elimination Programme. Civil 
                                                          
 
 
 
 
society organisations in Georgia have significantly improved hepatitis awareness amongst 
stakeholders and the general population, mobilising and involving communities in the policy-making 
process.  Separate national treatment programs are available in Georgia, Azerbaijan and Moldova. 
Treatment for viral hepatitis is offered as part of state programs in Armenia, Belarus, Kazakhstan, 
Kyrgyzstan, Russia and Ukraine.  
 
Mongolia provides an example for other high burden countries. According to a population based 
nationwide study done in 2008, the prevalence of viremic HCV infection was 11% and that of HBsAg 
was 11.8%, of whom 60% were also positive for hepatitis Delta antibody. According to 2016 national 
statistics of Mongolia, liver cancer is the most prevalent malignancy, at 44.0% of all cancers in 
Mongolia.  The Mongolian Parliament recently approved implementation of the Hepatitis 
Prevention, Control and Elimination Program 2016 to 2020, with the mission to eliminate HCV in 
Mongolia by 2020 and to significantly decrease the incidence of viral hepatitis, liver cirrhosis and 
HCC. The government allocated 232 billion Mongolian tugrug (96 million USD) for the program 
through 2020. By end of 2016, the Mongolian Government has included HBV and HCV medicines in 
the national health insurance, which covers 98% of the population. Therefore, the health insurance 
will provide 75$ for branded Harvoni and 65$ for generic Harvoni. As of 2018, approximately 20,000 
people have been treated by the new DAAs.  The cure rate for treatment of HCV infection is 98-99%. 
 
In 2015, Alliance for Public Health with support of Global Fund, launched treatment programme in 
Ukraine specially targeted at PWIDs providing DAA-based HCV treatment free of charge for over 
1900 people. Donor-supported programmes are also being implemented in Armenia and Belarus (by 
the Government of Georgia and Gilead), Uzbekistan (MSF), Kazakhstan (Abbvie), and Kyrgyzstan 
(Global Fund). 
 
Barriers to elimination [H3] 
 
Among the most vulnerable populations, particularly PWID, access to HCV services remains 
extremely limited due to stigma, discrimination and criminalisation. Viral hepatitis programmes 
targeted at PWIDs have been implemented only in Ukraine (by the Alliance for Public Health) and 
Georgia. Criminal responsibility for personal drug use (without intent to sell) is applied in all 
surveyed countries, and punitive drug laws and policies lead to levels of incarceration above the 
global average in Russia, Belarus, Georgia, Azerbaijan, Kazakhstan, and Moldova. PWID reportedly 
represent about one third of prisoners in the region, although they could make up between 50-80% 
of the prison population in some countries313.  
 
In countries where possession of micro-doses of drugs (eg >0.005g opium extract in Ukraine) 
classifies as a drug violation, harm reduction programmes face serious barriers, including the 
detainment and prosecution of outreach workers in possession of used (exchanged) syringes. As a 
result, drug users often refuse to participate in NSP, which are available in all surveyed countries but 
to widely varying degrees (eg, >1600 NSP sites in Ukraine, but only 4 sites in Russia). NSP services in 
prisons and criminal executive institutions are provided only in Armenia, Kyrgyzstan, Moldova, 
Ukraine and Tajikistan. Access to OST is also limited, with no programme in Uzbekistan and OST 
prohibited in Russia. Almost 900 patients from non-government-controlled areas of Donetsk and 
Luhansk oblasts were deprived of their OST since the beginning of the armed conflict between 
Russia and Ukraine, and the OST programme in Crimea was discontinued.  In Georgia, prisoners can 
receive OST only for detoxification in some pre-trial detention facilities. HCV treatment for 
individuals undergoing OST also occurs in prisons in Moldova. 
 
In April 2016, during the United Nations General Assembly Special Session, Ukraine, Moldova and 
Georgia, signed a statement 314 that harm reduction should be further promoted and implemented. 
It is important to note that these expressions of international support have not yet been matched by 
financial or political commitments. Some of the countries face a risk of breakdown in prevention and 
harm reduction services after decreasing of Global Fund support, as happened in Albania, 
Macedonia, Romania, Serbia, Montenegro and Russia. Despite some progress in Georgia, Kyrgyzstan, 
Ukraine, and Moldova, the state authorities in other countries, including Kazakhstan, Belarus, Russia 
and Azerbaijan, have not implemented prevention and harm reduction, noting lack of funding 
sources in majority of cases.  
 
Despite some progress in region, recent estimations indicate only 1% of people with HCV have 
access to treatment 312. Three countries (Azerbaijan, Georgia, Uzbekistan) can access generic 
daclatasvir (from Bristol Myers Squibb, BMS) thanks to the BMS agreement with the Medicine 
Patent Pool (MPP). Most others can potentially procure daclatasvir from the MPP licencees if there is 
no patent infringement. The bilateral Gilead voluntary licensing agreement for sofosbuvir covers 
Belarus, Kyrgyzstan, Tajikistan, Ukraine and Uzbekistan.  
 
In 2015-6, legal objections to patents for sofosbuvir were filed in Russia and Ukraine. In January 
2017, Ukraine approved an out-of-court settlement between Gilead and the state regarding the 
circumstances of registration. In Russia, the patent for sofosbuvir was opposed by NGO 
Humanitarian Action, which resulted in exclusion of pro-drug formula from the patent. Starting from 
January 2017, the drug manufacturer Nativa Ltd. is conducting generic sofosbuvir clinical trials in 
Russia. In Belarus, two versions of generic sofosbuvir were registered, and Belorussian and Egyptian 
drug manufacturers agreed to primary and secondary packaging of Egyptian generic sofosbuvir 
(Hepasoft) in Belarus.  
 
Whilst access remains limited, patients and carers have sought alternative ways to provide 
treatment. Procurement of generic DAAs through buyers’ clubs 315  is documented in four countries: 
Belarus, Kazakhstan, Russia, Ukraine. In Belarus, a buyers’ club is reportedly the main procurement 
source for treatment. 
 
Panel 9: Key priorities for action in EECA 
 Develop reliable national surveillance system both for hepatitis B and C, including 
key populations 
 Development and inclusion of antidiscrimination policy in national strategies with 
decriminalization of personal drug use without intention to sell  
 Ensure state funding to scale up harm reduction services including OST and NSP. 
 Integrate HCV services into harm reduction (simple service delivery model, peer 
support). 
 Continue raising awareness among the stakeholders and populations (both general 
population at those most-at-risk) 
 Advocate for accelerated registration of DAAs and application of different strategies 
including the use of TRIPS flexibilities for scaling up access to generics 
 Strengthen cooperation between CSOs and government and ensure community 
involvement at all levels of response to the epidemics 
 
Figure 11a The 10 countries with the greatest burden from viral hepatitis in Eastern Europe and 
Central Asia (data from Global Burden of Disease, 2016) 
Figure 11b Progress towards WHO elimination targets in the most heavily burdened countries of 
EECA (2017) 
 
  
  
Viral hepatitis in Oceania [H2] 
 
Australia, New Zealand, and Pacific Island Countries and Territories form part of the WHO Western 
Pacific Region, which has high viral hepatitis prevalence, particularly HBV, which causes a similar 
burden of mortality as for tuberculosis, HIV, and malaria combined316 . The region provides an 
illustration of the contrast between high and low-resource approaches to achieving global 
elimination targets for HBV and HCV infection.  
 
Australia and New Zealand are urbanised, high-income countries with universal free healthcare, 
heavily subsidised medications, and surveillance systems for notifiable infectious diseases, including 
viral hepatitis376. The estimated prevalence of HBsAg in 2015 was 1.0% in Australia and 4.1% in New 
Zealand, differences due in part to the size of the indigenous and migrant populations in the two 
countries. The prevalence of HCV is relatively low (1.0%)29,317-319, with most new infections occurring 
in PWID as in many other regions376. HBV and HCV cause significant morbidity and mortality in 
Australia and New Zealand 320,321, accounting for 1.4% and 1% of deaths, respectively, in 2013321, and 
the burden of viral hepatitis-related liver cirrhosis and HCC is rising. HCV accounts for 41% of annual 
cases of HCC, whereas HBV accounts for 22% of cases322,323. HCV is the commonest and HBV the 
third-commonest indication for liver transplantation in Australia and New Zealand, accounting for 
23% and 6% of all adult cases respectively324. Indigenous populations (eg, Aboriginal and Torres 
Strait Islanders in Australia, Māori in New Zealand) experience worse health outcomes and higher 
prevalences of disease compared with the population as a whole319. Indigenous populations have 
lower HBV vaccination rates, higher rates of injection drug use, and a higher prevalence of cofactors 
for liver fibrosis and carcinogenesis, including alcohol misuse and the metabolic syndrome154,325,326. 
Australia and New Zealand also have high levels of immigration, resulting in an increased prevalence 
of HBV and viral hepatitis as a whole327. 
 
The Pacific Island Countries and Territories are geographically, culturally, and socioeconomically 
diverse. Most are low-middle income countries, and an estimated 25% of the population lives in 
poverty328. The prevalence of HBV in the Pacific Island Countries and Territories ranges from 3% to 
23%329,330 (supplemental figure 8), and vertical HBV transmission of HBV persists despite timely birth-
dose vaccination, with 3–5% of infants born to HBsAg-positive mothers becoming HBsAg positive 
after vaccination331. This is attributed to high viral loads at time of delivery, lack of access to 
additional prevention strategies such as HBIg and nucleoside analogue therapy, and incomplete 
delivery of timely full vaccination schedule in some settings329. Data on HCV in this region are scarce  
(supplemental figure 8), but prevalence estimates are generally low (<0.5%)329,332-352. The prevalence 
of liver cirrhosis and liver cancer in this region is poorly characterised329,353,354, but 2016 estimates 
from the Global Burden of Disease Study show that mortality from viral hepatitis (predominantly 
HBV) exceeds that from malaria, HIV and TB combined for all of the Pacific Island Countries and 
Territories except Vanuatu and Solomon Islands329 . Additionally, obesity and type 2 diabetes are 
highly prevalent in the region and are important cofactors for non-alcoholic fatty liver disease, 
cirrhosis progression and liver cancer355,356. 
 
Success stories and ongoing challenges [H3] 
 
Australia and New Zealand have invested in strategies to increase access to testing and treatment 
for HBV and HCV, spearheaded by strong community advocacy, health research, health service and 
political leadership, and a commitment to the WHO 2030 elimination targets.  
 
Australia leads the world in some areas of its response to HCV, including having one of the world’s 
highest proportions of diagnosed individuals (~80%) among those infected318,357. Australia has also 
led the way in making HCV treatment universally accessible through an initial 5-year investment of 
over AUD$1 billion (approximately USD$720 million) in a risk-sharing arrangement with 
pharmaceutical companies. This arrangement enabled provision of DAA treatment for all chronically 
infected patients358-360, and boosted treatment uptake substantially, with over 30,000 people 
receiving DAAs in 2016361. Modelling studies suggests this approach is cost-effective and will be vital 
for achieving the 2030 targets (supplemental figure 9)362-364. Australia’s HCV program includes health 
promotion and education, GP-initiated treatment and nurse-led care, treatment in prisons, NSPs and 
OST for PWID, and prevention programs for sexual partners of infected individuals101,365. The 
governmental response to HCV in New Zealand is less advanced, but the country has made progress 
in improving access to treatment, reducing transmission via harm reduction strategies 366-370,473 and 
screen-and-treat outreach programmes371.   
 
Universal infant HBV vaccination and catch-up programmes are have been place in New Zealand and 
Australia for nearly two decades324,372,373 (supplemental figure 10), with resulting declines in HBV 
notifications, as documented in many other regions319,374. In New Zealand, universal vaccination has 
eliminated HBsAg prevalence in Māori children living in the eastern Bay of Plenty as of 1992375. New 
Zealand also has a successful community-based program of national HBV screening and 
surveillance—one of the largest in the world—and the Hepatitis Foundation of New Zealand has 
conducted national HBV screening and surveillance since 1998 as part of the Treaty of Waitangi 
initiative to close the gaps in health outcomes for Māori. The surveillance program has identified 
around 30,000 HBsAg carriers among adult Māori, Pacific and Asian New Zealanders (Ed Gane, May 
2018, personal commumication). However, in both Australia and New Zealand, indigenous 
communities have lower timely immunisation coverage, contributing to higher prevalence of HBV 
and related sequelae319,376,377. 
 
The HBV vaccination program in the Pacific Island Countries and Territories is one of the most 
effective globally. By 1997, all countries and territories had adopted a regionally coordinated HBV 
vaccination program331,378, with coverage in 2010 exceeding 80% everywhere except the Solomon 
Islands and Palau . 13 countries achieved the 2017 WHO milestones of  less than 1% HBsAg 
prevalence among 5-year-olds (as well as the interim 2012 milestone of <2% prevalence379-381), 
despite being ineligible for Gavi-supported vaccination programs and without 100% government 
funding382. The few countries with HBsAg prevalence above 2% in 2017, including Papua New 
Guinea, Solomon Islands, Kiribati, Samoa and Vanuatu, also had the highest HBsAg prevalence 
before 2012379,383. Novel strategies to improve hepatitis B vaccine birth dose delivery include use of 
vaccines outside of cold chain in Kiribati in geographically remote areas384. 
 
Barriers to elimination[H3] 
 
Despite subsidised HBV screening in Australia and New Zealand and specialist management and 
treatment for infected individuals, there are major barriers with regard to linkage to care. In 2012, 
57% of Australians with HBV were diagnosed, 13% were linked into care following diagnosis and only 
5% had received antiviral therapy385. Barriers to treatment include lack of awareness of the risks of 
HBV infection among patient populations, general practitioners, and health care workers386-392; 
inadequate guidelines for diagnosis by general practitioners and referral to specialist services; and 
underdeveloped shared care pathways between specialists, primary care physicians and nurses for 
patients with HBV393.  
 
Major challenges also remain in the Pacific Island Countries and Territories. Although this region has 
had great successes in HBV vaccination, coverage fell in some countries between 2010 and 2015, 
perhaps reflecting improved vaccination surveillance data but also loss of momentum, limited stocks 
and inadequate resources. Furthermore, catch-up vaccination programs for adults are inadequate331, 
and birth-dose vaccination delivery varies significantly across the region382,394-398. Many factors 
contribute to low vaccine uptake, including geographical isolation, limited access to antenatal 
screening, births outside health care facilities, inadequate vaccine supplies and cold chain systems, 
lack of Gavi funding for the monovalent vaccine, lack of skilled medical staff, and higher obstetric 
complication rates, the latter because health workers often withhold birth-dose vaccine when the 
infant is unwell, despite guidelines329,399-402. Neither HBIg nor antiviral therapy in the third trimester 
are routinely provided in most Pacific Island Countries and Territories due to prohibitive cost and 
limited supply329. HBsAg testing is provided free of charge in Fiji, Kiribati, Papua New Guinea, the 
Solomon Islands and Tonga, but only Kiribati has an HBsAg screening and linkage-to-care policy329.  
 
Key barriers to HCV screening include cost and the high false-positive rate for detection of anti-HCV 
antibodies due to cross-reactivity with malaria and dengue antibodies—an important issue for 
tropical countries with low HCV prevalence342,346,403,404.   
 
Lack of treatment access is another major constraint for both HBV and HCV elimination. Across the 
region, tenofovir is licensed only for HIV infection, not HBV mono-infection, and entecavir is not 
available. Moreover, tenofovir purchased outside of the Global Fund to Fight Aids, Tuberculosis and 
Malaria mechanism for HIV is several-times higher in price. Very few countries have state-funded 
treatment for either HBV or HCV (tenofovir is now licensed for use in Kiribati and this is in progress 
in Fiji), although pooled procurement options are being considered.  
 
The Pacific Island Countries and Territories remain hampered by insufficient resources to implement 
interventions, weak health infrastructure and weak disease surveillance programs, and few countries 
and territories can afford the cost of universal access to HCV and HBV therapy. Improved 
surveillance and data collection are also urgently needed. Australia and New Zealand are well placed 
to support universal access to antiviral treatment in the Pacific Islands and Territories by supporting 
negotiations with pharmaceutical companies, considering pooled procurement options to overcome 
the price negotiation barrier of small national populations, and funding for regional treatment 
initiatives. Plans to extend New Zealand’s HBV screening and surveillance into Samoa and Tonga in 
development (Ed Gane, Auckland City Hospital, May 2018, personal communication) is a positive 
step. 
 
Figure 12a The 10 countries with the greatest burden from viral hepatitis in Eastern Europe and 
Central Asia (data from Global Burden of Disease, 2016) 
Figure 12b Progress towards WHO elimination targets in the most heavily burdened countries of 
EECA (2017) 
 
Panel 10: Key priorities for action in Australasia and the Pacific Islands & Territories 
 
 Healthcare worker and community education to increase awareness and demand 
for testing  
 National government and advocacy group-led public health campaigns to reduce 
stigma associated with viral hepatitis 
 Investment in improved HBV vaccine birth dose delivery 
 Improved surveillance and data collection systems to outline, monitor and evaluate 
progress towards elimination goals 
 Investment in health workforce and health system infrastructure 
 Government subsidised, quality-controlled diagnostic testing for HBV and HCV 
 Universal access to HBV and HCV treatment through initiatives such as pooled 
procurement and use of generics 
 
  
Sustaining Progress towards Hepatitis Elimination [H2] 
 
There is no doubt that the once-in-a-generation transformation of HCV treatment has energised the 
movement towards elimination of not just HCV, but also HBV – with scalable treatment options now 
available for both these major infections. The last 3 years have seen substantial progress towards 
elimination, including the universal adoption by countries of the WHO Global Health Sector Strategy 
in 2016 and adoption of more detailed regional action plans; the specific inclusion of viral hepatitis 
in the Sustainable Development Goals; the emergence of next-generation pan-genotypic DAA 
treatment options for HCV treatment; the singular success in the Western Pacific Region of reducing 
MTCT; the highly publicised HCV elimination plans in Georgia and Egypt; and the launch of NOhep, 
the global hepatitis elimination movement. These achievements deserve to be celebrated, but the 
challenge now is sustaining this momentum, in order that the ambitious WHO elimination goals can 
be achieved.  
 
In this commission we have emphasized the different pace of progress in different regions of the 
world. This presents an important opportunity to share learning, from both successes and mistakes 
and identify those approaches which will best suit individual countries. Of the 20 highest burden 
countries (figure 1xx), some (e.g. India, Nigeria, Russia and Bangladesh) have yet to make significant 
progress towards elimination, particularly for hepatitis C.  There are still countries, especially in the 
Eastern Mediterranean and African regions that are struggling to implement the HBV birth dose 
vaccine, but most have now committed to action.  Yet others, like Egypt and Australia are moving 
faster.  
 
International organisations have a key role in supporting national progress and they need to ensure 
that viral hepatitis is part of their remit, on a par with other major infectious diseases like TB and 
HIV. Some organisations have been leaders in this regard, notably the WHO, UNITAID and CHAI, but 
more can be done. There are several areas these and other organisations can prioritise to support 
hepatitis elimination efforts (see Table of Priority areas). Some are specific to hepatitis, for example 
the need to support the scale up of birth dose vaccination which should fall within the Gavi remit for 
support (see section 2). Several others can leverage existing mechanisms supporting other disease 
responses, notably HIV, to improve access to care and treatment.  
 
Ensuring good quality data on the burden of disease is crucial to inform global policy. This 
commission has emphasized data from the Global Burden of Disease programme which combines 
data on mortality with years of healthy lives lost estimate the burden of viral hepatitis (DALYs). This 
is provides additional information to most estimates (including WHO) which focus on the numbers of 
those affected and annual deaths. The distinction is important as it places hepatitis within the 
context of other disease when prioritizing finite health resources. It has to be hoped that the recent 
announcement of a partnership between IHME (who produce the Global Burden Estimates) and 
WHO will allow both to be presented together more regularly. 
 
There has been real progress in to improving access to generic medications. Whilst drug access 
remains a global priority, particularly in relation to access to pan-genotypic regimens (notably 
glecaprevir/pibrentasvir, see section 4), this commission also emphasises the importance of 
diagnostics. Greater innovation is required to develop new diagnostics that are suitable for high 
burden/low resource countries, to ensure high quality care. The recent establishment of a WHO 
Essential Diagnostic List is a welcome recognition of this importance. This now needs to be matched 
by greater focus on pre-qualification to ensure provision of high quality diagnostics  and providing 
clinical evidence for simplified management algorithms where diagnostics are not available.  
 
Despite the burden of disease and existence of cost-effective interventions, there is currently no sign 
that a new global mechanism for funding viral hepatitis will be implemented to support the 
expansion of testing and treatment, nor is the Global Fund likely to expand its remit in the short 
term. This places an onus on countries to develop new fiscal space to accelerate elimination, which 
may require innovative means of financing. Financing the scale up of testing is the key challenge to 
elimination, and sustaining progress will require not only financing but also strong political will and 
unrelenting advocacy. 
 
Supporting countries to finance their hepatitis programs as part of universal healthcare coverage is 
vital, and potential  approaches have been outlined within the commission (section 4). The costs of 
drugs and diagnostics remain a concern, but falling drug costs for both HBV and HCV, mean that 
investment in hepatitis has the potential to be not only cost-effective, but cost-saving. As such, 
greater emphasis will need to be placed on returns on investment in hepatitis programmes.198 
Benefits of national hepatitis plans go beyond elimination of viral hepatitis, as many of the required 
prevention measures will help to strengthen the health system as a whole. Infection control, blood 
safety, safe and rational injecting practices, and harm reduction are key examples. These added 
benefits need to continue to be defined and articulated for national programs198.  
 
Whereas most countries have had active HBV vaccination programmes for many years, broadening 
these efforts to include HCV requires a significant change in thinking for some governments, given 
the broader social issues involved and the absence of an effective HCV vaccine. Governments serious 
about developing actionable national plans will need to ensure wide engagement with stakeholders 
to include individuals and organisations representing at-risk groups (eg PWID, prisoners and 
individuals with HIV). Nowhere is this more challenging, and more important, than in parts of the 
world where risk behaviours remain criminalised and the health and criminal justice systems are 
poorly integrated. Sustaining progress will require political will and continued advocacy.  
 
Political will is complex and can be driven by a variety of factors, often in combination. It can be 
driven by personal factors, or it can be motivated by the sheer scale of a public health problem (as in 
Mongolia, where the death toll from viral hepatitis is so high that it automatically becomes a 
national priority).  Political will can also be generated by advocacy or by patiently engaging policy-
makers in a way that allows them to feel they can make a difference. To support this, more 
initiatives are needed to foster the development of regional champions within civil society, 
professional bodies and policy circles. In writing this Commission we have sought wherever possible 
to draw on expertise within high burden countries, but there is a still a need for a wider range of 
voices advocating change. This requires support with similar investment in advocacy for hepatitis to 
that seen for HIV.  
 
It is likely that a select number of smaller countries, e.g. Iceland and Georgia will be able to achieve 
the WHO elimination goals well ahead of schedule, and possibly even eradicate infection. For larger, 
more heavily-burdened countries, aiming to eliminate HBV or HCV infection in key sub-populations 
(microelimination) offers achievable intermediate steps towards elimination. Examples of successful 
microelimination efforts already exist such as the efforts achieving elimination of HBV in those under 
20 in Alaska discussed in section 5.3. This will become particularly important as countries make 
progress towards nationwide elimination, and provide success stories to maintain political will if 
progress itself reduces the immediate imperative for action as mortality and prevalence rates fall. 
 
Unless significant progress is made in the highest burden countries with some of the greatest 
challenges, elimination targets will not be achieved. Governments should expect to be held 
accountable for their progress toward national hepatitis elimination strategies, and it is reasonable 
for those providing funds to ask for evidence of the impact of that funding. Data on progress to 
achieve elimination targets will be regularly reported by WHO and others, but more attention needs 
to be paid to national performance relative to other countries. The structure of the  WHO, reporting 
as it does to its member states, makes it harder for WHO alone to identify those countries lagging 
behind and other measures of progress. 
 
The development of the first health-related index measuring progress towards the sustainability 
development goals (SDG) 405 is a helpful example, but has its limitations. The SGDs monitor the 
prevalence of HBsAg in those under 5 as an  good indication of progress in vaccination and 
preventing mother-to-child transmission, but this doesn’t account for those with chronic infection in 
need of treatment. The absence of any single meaure of progress for HCV within the SGDs  is more 
concerning. A Hepatitis Elimination Index needs to be developed to assess progress towards national 
elimination targets. Some early work on this has begun within the Polaris Observatory. However, 
such initiatives are costly and need to be funded as a priority to ensure momentum is maintained 
towards elimination. 
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